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Abstract
It is of importance to understand which nanoparticle properties that govern the in-
teractions between particles and cells, in order to develop a nanocarrier with the de-
sired functionality. In this thesis, nanoparticles made of biodegradable poly(alkyl
cyanoacrylate), with either butyl or octyl as the side chain, and with different
polyethylene glycol (PEG) surface coatings, have been utilized. The objective was
to determine whether variations in these properties influenced cellular uptake and
toxicity in prostatic adenocarcinoma cells, as well as the release of a model drug,
nile red.
Cellular uptake of nanoparticles was investigated in vitro using flow cytometry
and confocal laser scanning microscopy. It was established that the encapsulated
nile red marker could dissociate from the particles, thus making evaluation of
cellular uptake difficult. No alterations in PEG type or chain lengths made nile
red remain in the particles to such a degree that endocytosis of nanoparticles could
be detected. Spectrophotometric analyses of nile red release from the nanoparticles
and into cell medium demonstrated that ∼45% or more of originally encapsulated
nile red was released after 3 hours. This confirmed high nile red release from the
particles, and at the same time it showed that changes in PEGylation did not
reduce the release to any extent. After estimating PEG chain surface densities, it
was evident that all particles had very low PEG densities, providing an explanation
to why nile red dissociated from the particles to such a high degree: the PEG layer
did not shield a large enough part of the particle surface area to effectively hinder
release of nile red.
Cytotoxicity after nanoparticle exposure was determined using an assay measuring
the metabolic activity of cells. Toxicity was found to be strongly dependent on
the length of the alkyl side chain in the monomer, where the longest chain, with
the lowest degradation rate, was the least toxic. Altogether, this suggests toxicity
induced by release of degradation products, but it can also be attributed to residual
surfactant from the synthesis, as the observed cytotoxicity was higher than what
is reported in literature for similar nanoparticles.
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Sammendrag
Det er svært viktig a˚ forst˚a hvilke egenskaper ved nanopartikler som styrer in-
teraksjonene mellom partikler og celler for a˚ utvikle en partikkel med ønsket
funksjonalitet. I denne masteroppgaven har nanopartikler laget av biodegrader-
bar poly(alkyl cyanoakrylat), med enten butyl eller oktyl som sidekjede, og med
ulike polyetylen glykol (PEG) lag p˚a overflaten, blitt benyttet. Ma˚lsetningen var
a˚ bestemme hvorvidt variasjoner i disse egenskapene p˚avirket opptak og toksisitet
i prostatiske adenocarcinom celler, i tillegg til frigjøring av en modell cytostatika,
nilrød.
Opptak av nanopartikler i celler ble undersøkt in vitro ved hjelp av flow cytometri
og konfokal laser skanning mikroskopi. Det ble fastsl˚att at innkapslet nilrødt kunne
dissosiere fra partiklene og dette gjorde evalueringen av cellulært opptak vanskelig.
Ingen endringer i PEG type eller PEG kjedelengde resulterte i at nilrød forble i
partiklene i stor nok grad til at endocytose av nanopartiklene kunne detekteres.
Spektrofotometriske ma˚linger av nilrødt frigjort fra nanopartiklene i cellemedium
p˚aviste at ∼45% eller mer av den opprinnelige mengden nilrødt innkapslet i par-
tiklene kunne frigjøres i løpet av 3 timer. Dette bekreftet høy nilrød frigjøring
fra partiklene, samtidig som det viste at endringer i PEGylering ikke p˚avirket
frigjøringen i noen grad. Etter a˚ ha estimert overflatetettheten av PEG kjeder
ble det tydelig at alle partiklene hadde svært lave PEG tettheter, noe som ga
en forklaring p˚a hvorfor nilrød dissosierte fra partiklene i s˚a stor grad: PEG laget
beskyttet ikke en stor nok del av partikkeloverflaten for a˚ effektivt hindre frigjøring
av nilrødt.
Cytotoksisitet etter nanopartikkel eksponering ble bestemt ved a˚ bruke et assay
som m˚alte cellenes metabolske aktivitet. Toksisiteten var svært avhengig av leng-
den p˚a alkyl sidekjeden i monomeren, der den lengste kjeden, med lavest degrader-
ingshastighet, var den minst toksiske. Alt i alt tydet dette p˚a at toksisiteten var
for˚arsaket av frigjøring av degraderingsprodukter, men den kan ogs˚a skyldes gjen-
værende surfaktant fra syntesen, siden den observerte cytotoksisiteten var høyere
enn det som er beskrevet i litteraturen for lignende nanopartikler.
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1 Introduction
Cancer is a group of diseases characterized by uncontrolled and abnormal cell pro-
liferation and metastasis. None of the existing therapies (surgery, radiation and
chemotherapy) have been able to prevent an increase in number of cancer deaths
during the past 70 years [1], and with more than 12 million new cases occurring
every year [2], cancer remains one of the world’s most devastating diseases. Ad-
ditionally, administration of chemotherapeutic drugs cause severe side effects in
patients and can also damage healthy tissue. [3] This calls for the development of
new methods for improved cancer diagnosis and treatment.
General progress in the field of nanotechnology has given a continuous increase
in understanding the potential that comes from using nanoparticles in biomedi-
cal applications. [4] Nanocarriers, which can be loaded with a contrast agent [5],
anticancer drug [6] or both [7], are developed to create safer and more effective
therapeutic and diagnostic modalities. The nanoparticles can have unique physical
and biological properties, carefully designed to overcome current limitations with
molecular imaging and drug delivery to tumors. Such nanoparticle systems hold
considerable promise as the next generation cancer medicine that enable early
detection, delivery of targeted therapy, monitoring of therapeutic response and
minimization of adverse effects. [8, 9, 10]
The work with this master’s thesis has been carried out as a part of a collaboration
project between NTNU, SINTEF and St. Olavs Hospital called ”Multifunctional
nanoparticles in cancer diagnosis and therapy”. SINTEF Materials and Chemistry
has developed a one-step synthesis route for poly(alkyl cyanoacrylate) nanoparti-
cles which are intended for use as carriers of therapeutic and/or contrast agent.
The novelty with these nanoparticles is their ability to stabilize microbubbles. To-
gether with applied ultrasound, the microbubbles can function as contrast agents
in ultrasound imaging, and at the same time improve drug delivery by enhancing
the transport across vasculature and into cancerous tissue. The prospective goal is
to achieve a multifunctional nanoparticle system that can be used for simultaneous
monitoring and treatment of cancer.
To develop a nanocarrier with properties that can fulfill this goal, it is crucial to un-
derstand the interactions between nanoparticles and cells. Many pharmacological
targets are located intracellularly [11], and consequently such drugs must be taken
up by cancer cells for the delivery to be successful. This is possible either by endo-
cytosis of the nanomedicine and subsequent intracellular release, or extracellular
release followed by drug diffusion across the cell membrane. Both these processes
will depend on interactions at the nanoparticle-cell interface. Additionally, other
important features of nanoparticle systems are influenced by these interactions,
2e.g. cytotoxicity and circulation times. Research suggests that the interactions at
the nano-cell interface mainly are affected by the size and surface properties of the
particles. [12, 13, 14] One common way of altering surface properties is to coat the
nanoparticle with polyethylene glycol (PEG). [15, 16] An increased understanding
on how different nanoparticle properties influence their interactions with cells can
eventually result in much needed knowledge on how to design a nanocarrier with
the desired characteristics.
In my project work ”Investigation of cellular uptake of PBCA nanoparticles” [17],
the results clearly indicated that interactions at the particle-cell interface were
affecting cellular uptake of a lipophilic, fluorescent probe: nile red. It was estab-
lished that the transfer of nile red from nanoparticles into cells was mainly driven
by diffusion, and the process was hypothesized to stem from collisions between par-
ticles and the cell membrane. Based on this discovery, it was seen as important to
learn more about how the poly(alkyl cyanoacrylate) nanoparticles are interacting
with cells. Therefore, in this thesis, the effect of nanoparticle properties on cellular
uptake, hydrophobic probe release and cell viability have been investigated, with
emphasis on the influence of PEGylation and monomer composition. The utilized
nanoparticles have been coated with PEG chains of different type and length, and
prepared from two monomers with different side chain lengths: butyl- and octyl
cyanoacrylate. In addition, since partition of nile red from the nanoparticles com-
plicated the analysis of cellular uptake in the project work, nanoparticles labeled
with different fluorescent markers have been tested and evaluated as a part of this
study.
2 Theory
2.1 Nanoparticle applications in medicine
A wide variety of nanoparticle systems intended for use in the medical field are
under development today. Nanoparticles for medical applications are defined as
particles with a size between 1 and 1000 nm [18], and thereby they offer the
possibility to interact with and influence cellular entities and processes at their
natural scale. These biomimetic features, together with high surface to mass ratio
and ease of introducing new properties or modifying already existing properties,
give nanoparticle systems the potential of bringing significant advances in the pre-
vention, diagnosis and treatment of disease. Nanoparticle systems are therefore
being exploited in diverse medical applications such as imaging, drug and gene
delivery, photothermal therapy and biosensors. The constant increasing interest
for nanoparticles in medicine has made the need for a common term for these
applications evident. Nanomedicines are thus defined as the use of nanoscale or
nanostructured materials that according to their structure have unique medical
effects in both diagnosis and treatment of disease. [19] Examples of nanoparticle
platforms investigated for biomedical purposes include polymeric, ceramic, mag-
netic, solid-lipid and viral-based nanoparticles, liposomes, micelles, dendrimers
and carbon nanotubes [20, 21], where some are depicted in figure 2.1.
Figure 2.1: An illustration showing some nanoparticle systems commonly used in medical
applications. [20]
4 Nanoparticle applications in medicine
The first generation of nanomedicines have already been approved by the U.S.
Food and Drug Administration (FDA), and are available on the market. In fact,
if polymer therapeutics (i.e. polymer-drug conjugates) are included, more than
40 products have completed the translation from laboratory to clinical use. [22]
In table 2.1, a representative selection of FDA approved nanomedicines is given.
From this overview it is worth to note that significantly more nanomedicines have
entered routine clinical practice for therapeutics than for imaging.
Table 2.1: Examples of FDA approved nanomedicines. [22, 23]
Product name Technology Indication Approval
Abelcet Liposomal amphotericin B Fungal infections 1995
Abraxane Albumin-paclitaxel
nanoparticles
Metastatic breast
cancer
2005
Cimzia PEGylated fragment of an
anti-TNF antibody
Crohn’s disease and
rheumatoid arthritis
2008
Copaxone Glutamine, Alanine,
Tyrosine copolymer
Multiple sclerosis 1996
DaunoXome Liposomal daunorubicin HIV-associated
Kaposi’s sarcoma
1996
Depocyt Liposomal cytosine
arabinoside
Cancer 1999
Doxil/Caelyx PEGylated liposomal
doxorubicin
Various cancer types 1995
Emend Nanocrystal particles Chemotherapy related
nausea and vomiting
2003
Gastromark Silicon-coated SPIONs MRI contrast agent 1996
MultiHance Gadolinium-based
nanoparticles
MRI contrast agent 2004
Pegasys PEG-interferon alpha Hepatitis B and C 2002
Visudyne Liposomal verteporfin Age-related macular
degeneration
2000
Abbreviations: Superparamagnetic iron oxide imaging nanoparticles (SPIONs)
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2.1.1 Nanoparticles as drug delivery systems
Drug delivery mediated by nanoparticles is an intriguing field of research that has
captured the interest of scientists worldwide. This is illustrated by how around
75% of all scientific publications within the field of nanomedicines center around
this topic. [19] The development of effective drug delivery systems that can trans-
port and deliver a drug precisely and safely to its site of action is the motiva-
tion behind this massive research effort. A safe and targeted drug delivery can
improve the performance of some traditional drugs already on the market, and
furthermore contribute to the development of novel therapeutic strategies such as
peptide and protein delivery, glycoprotein administration, gene therapy and RNA
interference. [24]
A nanoparticle drug delivery system is made by encapsulating or attaching a ther-
apeutic agent to a nanoparticle platform. (See figure 2.1 for examples of nanocar-
riers.) These systems offer potential solutions for current challenges in treating
cancer, cardiovascular and neurodegenerative diseases, in addition to several other
illnesses. [23] The aim with nanoparticle drug delivery systems is to administer
the drug through controlled delivery, such that an optimum amount reaches the
target site, resulting in increased efficacy of treatment and maximized patient
compliance. In addition, these systems can provide new opportunities with drugs
that were rendered useless because of high toxicity, high dosage requirements, poor
solubility and short circulation times in vivo. Table 2.2 summarizes some of the
achievable advantages with nanoparticle drug delivery systems.
Table 2.2: Advantages with nanoparticle drug delivery systems. [21, 25, 26]
• Provide targeted delivery
• Improve bioavailability
• Decrease toxic side effects
• Protect the drug from degradation
• Increase the aqueous solubility of the drug
• Reduce total body dose of drugs
• Simultaneously deliver multiple drugs
• Improve crossing of biological barriers
• Produce a prolonged release of drugs
• Offer appropriate form for all routes of administration
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The most notable advances in nanoparticle mediated drug delivery have been in
the field of oncology. [27] This can be illustrated by how several products in the
anticancer segment have been FDA approved. Doxil R©/Caelyx R© and Abraxane R©
(see table 2.1) are two main examples of drug delivery nanocarriers with success
in the clinic. The chemotherapeutic agents doxorubicin and paclitaxel are both
very effective in killing cancer cells, but their use is limited when administered
alone because of severe side effects. When these drugs are associated with their
respective nanocarrier (doxorubicin encapsulated in liposomes and paclitaxel as-
sociated with albumin nanoparticles) patients experience lower systemic toxicity
and can benefit from improved therapeutic efficacy. [28, 29, 30, 31] More details
about nanomedicines in cancer therapy will follow in section 2.3.
2.1.2 Nanoparticle systems as contrast agents in imaging
For many of the same reasons that nanoparticles are utilized as drug carriers,
their unique features are being exploited as contrast agents in biomedical imaging.
The use of contrast agents are standard practice in such imaging since they are
necessary to achieve adequate image quality. [32] Contrast agents function to en-
hance image contrast and improve the visibility of features that otherwise would
be difficult to detect. Ultrasound, magnetic resonance imaging (MRI), X-ray and
computed tomography (CT) are examples of non-invasive imaging modalities that
can benefit from the development of nanoparticle contrast agents.
The prospective goal with improving existing imaging techniques by utilizing
nanoparticle contrast agents, is to develop diagnostic procedures to image patho-
genic processes on a molecular level. [18] Such molecular diagnostics might be
essential both for early diagnosis and understanding the underlying processes of
many diseases. Areas where nanoparticle contrast agents can be advantageous
include imaging for guided surgery, imaging of gene expression in vivo to elucidate
disease development, and monitoring of drug efficacy. [33] In addition, the ability
to image and track the fate of a nanomedicine in vivo will be of great importance
in the development of effective drug delivery systems.
A nanoparticle contrast agent is made by loading of a contrast enhancing agent
into a nanocarrier, or the nanoparticles can function as contrast agents them-
selves. Table 2.3 gives some examples of nanoparticle systems utilizing different
contrast mechanisms, according to which imaging modality they are intended for.
Compared with conventional molecular-scale contrast agents, nanoparticle systems
offer the possibility of targeting to sites of interest and increased circulation times
allowing for prolonged imaging. As of today, only nanoparticle based contrast
agents for MRI imaging have been approved for clinical use. (See table 2.1)
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Table 2.3: Nanoparticle systems for various imaging techniques
• Gold nanoparticles as X-ray contrast agent. [34]
• Magnetic nanoparticles as MRI contrast agent. [35]
• Microbubbles with immobilized nanoparticles on the surface as
ultrasound contrast agent. [36]
• Quantum dots as optical labels in fluorescence imaging. [37]
• Radiolabeled nanoparticles for positron emission tomography
and single-photon emission CT. [38]
2.1.3 Multifunctional nanoparticles
The applications described above demonstrate how nanoparticle systems have
great potential in prevention, detection and treatment of disease. From this knowl-
edge, new technology combining these properties is emerging. Whereas monofunc-
tional nanoparticle systems provide a single function, multifunctional nanoparticles
are engineered to have different functionalities in one construct. Multifunctional
nanoparticles that can target, monitor and treat the site of disease simultaneously
are being exploited. A potential multifunctional nanoparticle system is illustrated
in figure 2.2. Here, the nanoparticles are functionalized with a targeting ligand,
and loaded with MRI contrast agent and therapeutic agent. The particles are thus
multifunctional; they offer possibilities for targeting to a diseased site, enhanced
contrast with MRI imaging and drug delivery. In addition, the nanoparticles can
be immobilized on the surface of microbubbles and in this manner allow ultrasound
imaging with improved contrast. By using a construct that contain both thera-
peutic and contrast agent, the distribution and effect of drugs can be monitored
in vivo. Such platforms, where disease diagnosis and therapy are combined, are
generally referred to as theranostic nanoparticles. [39]
A summary of the different properties it is possible to incorporate in a multifunc-
tional nanoparticle system is given in table 2.4. Production of nanoparticle systems
that contain some or all of the mentioned properties remains a challenge, and one
of the limitations is the surface chemistry required. [40] Adding multiple functions
on a single particle usually means additional synthesis steps and costs, and the re-
alization of such systems is clearly dependent on advances in chemical techniques.
Moreover, a multifunctional nanoparticle system will have more complex effects
and behavior in vivo, and also greater regulatory hurdles. The trade-off between
additional functionality and complexity is the subject of ongoing debate. It is
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Figure 2.2: An illustration showing a potential multifunctional nanoparticle system
which combines possibilities of imaging and drug delivery. The nanoparticles on the
left have a targeting ligand on the surface and are incorporated with a drug and MRI
contrast agent. On the right, the same nanoparticles are attached to the surface of
microbubbles which can be utilized as contrast agents in ultrasound imaging. Figure
adapted from Y´rr Mørch, SINTEF Materials and Chemistry.
Table 2.4: A summary of different properties it is possible to incorporate in a multifunc-
tional nanoparticle system. [40]
Property Functions
Therapeutic agent Released to treat diseased site.
Targeting ligand Recognizes target cells to increase efficiency and re-
duce toxicity of therapeutic agent.
Imaging agent Report real-time nanoparticle distribution and mon-
itor drug transport such that therapeutic efficacy of
drugs can be evaluated.
Cell-penetrating agent Facilitate entry of nanoparticle systems into cells.
Can modify nanoparticle pharmacokinetics and bio-
distribution, and increase drug efficacy.
Stimulus sensitive agent Responds to stimulus to release encapsulated agents.
Controls bioavailability and reduces toxicity of drugs.
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claimed that addition of targeting ligands and imaging capabilities to therapeutic
nanoparticles is worth the additional complexity of synthesis, cost and regulatory
hurdles. [41]
2.1.4 PEGylation of nanoparticles
Parts of this section are taken from my project work. [17]
No matter which function a nanoparticle system is intended to have, one feature
will be in common; it needs to be able to maintain in the body for a long enough
time to reach its site of action. A significant obstacle to the long-term circulation
of nanoparticles, is clearance by the mononuclear phagocyte system (MPS). When
nanoparticles are employed in the body, plasma proteins adsorb on the particle
surface, targeting the carrier for elimination. Phagocytic cells in blood and tissue
can then recognize the nanoparticles as foreign material, engulf them and transport
them to the liver and spleen for degradation and excretion. The MPS has the
ability to clear intravenously administered nanocarriers from the blood within
minutes. [42] Therefore, nanoparticles developed for systemic application need to
be engineered to avoid elimination by the MPS.
Unquestionably, the most successful approach to impart stealth properties on nano-
particles, is coating the particle surface with a PEG layer. PEG is a coiled, hy-
drophilic polyether compound that can be covalently attached, adsorbed or grafted
to the surface of a nanoparticle. Addition of a PEG coating to the nanoparticle
surface reduces MPS uptake and increases circulation time when compared to
uncoated particles. [16] This is mainly because PEG has the lowest level of pro-
tein or cellular adsorption of any known polymer [43], thus making a nanoparticle
coated with PEG unrecognizable for the plasma proteins in the blood stream.
The circulation half-life of liposomes has been extended to more than 60 hours by
PEGylation. [44]
The most acknowledged theory to explain why PEG improves stealth properties
of nanoparticles is based on interactions between proteins and the PEGylated
surfaces. When plasma proteins in the blood stream approach the particles, they
will compress the surface layer of PEG chains. Upon compression, the PEG layer
is forced into a higher energy conformation, which will create an opposing force.
This force can completely balance and/or overpower the attractive force between
the plasma proteins and the particle, resulting in less or no attachment of proteins
to the surface. [45] For this process to be effective, the PEG layer must exceed a
minimum thickness. The thickness can be hard to control and is therefore usually
put in connection with factors like PEG chain molecular weight and surface density.
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Most research indicates that a PEG chain molecular weight of 2000 Da or greater
is required to achieve decreased uptake by the MPS [45], meaning this molecular
weight is believed to give a PEG layer exceeding the minimum thickness needed.
Depending on the PEG density, there are two main surface conformations the
PEG layer can take. If the surface coverage is low, the PEG chains will usually
take on a ”mushroom” formation, whereas high surface coverage leads to a ”brush”
configuration. The two conformations are illustrated in figure 2.3. PEG chains in a
mushroom formation will on average be located close to the particle surface, while
in the brush formation the chains will extend from the particle surface. A high
surface density will make sure that no gaps in the PEG layer are present (occurs
with too low density), but on the other hand, it will lead to restricted mobility and
thus reduced steric hindrance properties of the PEG layer. Hence, theoretically, the
optimal surface coverage will lie somewhere in between that of the mushroom and
brush configuration. [45] It is also reported in literature that nanoparticles with an
intermediate mushroom/brush configuration were most resistant to phagocytosis
and activated the human complement system poorly. [46]
Figure 2.3: Schematic diagram showing the PEG layer conformation on a nanoparticle
surface. (a) shows a nanoparticle with low density of PEG, thus resulting in a PEG
layer in a ”mushroom” conformation, and (b) illustrates a nanoparticle with high surface
density of PEG leading to a ”brush” conformation. [45]
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Attention has to be made that PEGylation of nanoparticles is not exclusively pos-
itive. Nanoparticle systems are dependent on efficient delivery of their contents
when they reach the target site. The PEG coating may be an obstacle in realizing
desired therapeutic response by hindering delivery of therapeutic agent and/or in-
terfering with target cell interaction. [47] The first effect has been demonstrated
by showing how PEG coating of nanoparticles compromises intracellular delivery
of genes. [48] In a recent article, it was observed that high PEG surface density
on nanoemulsions decreased the efficacy of targeting to angiogenic tumor vascu-
lature [49], providing evidence for the second unfavorable effect. Besides this,
immune reactions to PEGylated liposomes have also been reported. [50, 51]
2.2 Polymeric nanoparticles
After being extensively studied, polymeric nanoparticles for biomedical applica-
tions are today in various stages of research. Since polymer chemistry is a ver-
satile field, the particles can be manufactured from a wide range of polymers,
both synthetic and natural in origin. The selected polymers must fulfill several
requirements, like biocompatibility with tissue and cells, controlled- and sustained
release properties, suitable degradation kinetics and mechanical properties and
ease of processing. [52, 53] In general, synthetic polymers have the advantage of a
sustained release of therapeutic agent over a period of days to several weeks when
compared to natural polymers with a relatively shorter duration of release. [54]
On the other hand, their application in vivo can be limited by the use of organic
solvents and harsh conditions during preparation. Table 2.5 gives a summary of
the most common polymers used in the manufacture of nanoparticles for medical
purposes.
In the past decades there has been considerable interest in developing biodegrad-
able nanoparticles for applications in the medical field. The use of biodegradable
materials ensure that the polymer is degraded in vivo through either simple chem-
ical reactions or enzyme-catalyzed reactions. [56] To assure that the polymer is
also eliminated from the body without residual side effects, biodegradability is not
enough; the polymer needs to be resorbable as well. The degradation byproducts
from bioresorbable polymers can be eliminated through natural pathways, either
by simple filtration or after being metabolized. [57] One class of such bioresorbable
polymers is the poly(alkyl cyanoacrylates). They have been investigated for fab-
rication of biomedical nanoparticles for more than 20 years [58], and the interest
has not decreased by seeing how poly(isohexyl cyanoacrylate) nanoparticles loaded
with doxorubicin (Transdrug R©) for treatment of advanced hepatocellular carci-
noma reached phase III clinical trials in 2012. (Clinical trial ID: NCT01655693)
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Table 2.5: An overview of the most frequently used polymers in the fabrication of
nanoparticles for biomedical applications. [55]
Synthetic polymers Natural polymers
Polyesters
• Polylactides
• Poly( -caprolactone)
• Poly(phosphoesters)
• Poly(ortho esters)
Polyanhydrides
Polyphosphazenes
Poly(alkyl cyanoacrylate)
Proteins
• Albumin
• Collagen
Polysaccharides
• Cellulose
• Alginate
• Chitosan
• Pullulan and dextran
• Hyaluronic acid
• Ulvan
Polyhydroxyalkanoates
Figure 2.4: Chemical structure of poly(alkyl cyanoacrylates), where R denotes the alkyl
group and n the number of repeating units.
In vivo, poly(alkyl cyanoacrylate) nanoparticles undergo surface degradation. The
main pathway is by hydrolysis of the ester bond on the alkyl side chain of the poly-
mer [59, 60], and the rate of degradation has been shown to decrease with increasing
length of the alkyl side chain. [61] A representation of the chemical structure of
the polymer is given in figure 2.4. Esterases from serum seem to be important for
catalyzing the hydrolysis reaction [62], and the generated byproducts, alkylalcohol
and poly(cyanoacrylic acid), are eliminated through kidney filtration. [63] Even if
the polymer is classified as bioresorbable, it is important to note that the complete
removal of polymeric material only occurs if the nanoparticles are prepared from
low molecular weight polymers. [55]
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2.2.1 Toxicity of biodegradable polymeric nanoparticles
The three main outcomes of cellular toxicity are cell death, genotoxicity and in-
flammation. Assessment of possible toxicity after exposure to polymeric nanopar-
ticles is therefore a critical factor to consider when evaluating their potential in
biomedical applications. It is believed that the toxic potential of nanoparticles
are due to the chemical composition of the parent material, interactions at the
nanoparticle-biological interface, or a combination of both.
To avoid adverse effects of biodegradable polymeric nanoparticles it is important
to ensure that the composition of the polymer is not toxic by itself, and what
cellular responses are induced by degraded particles. After administration of a
nanomedicine, the intact polymeric structure will after a time start to degrade.
This process results in potentially hazardous polymeric residues and degradation
products of different sizes being exposed to the biological environment. Biode-
graded nanoparticles may cause harm by accumulating within cells and thereby
leading to intracellular changes such as disruption of organelle integrity or gene
alterations. [64] The degree of toxicity is influenced by the degradation rate of the
nanoparticles, which again is dependent on the composition of the particle and
the biological conditions of the local environment. [65] One example is poly(alkyl
cyanoacrylate) nanoparticles, where several studies have demonstrated how cyto-
toxicity clearly depends upon the degradation rate of the polymer. [66, 67]
Polymeric nanoparticles for medical purposes are designed to deliberately inter-
act with cells and tissue. This pose a risk since the interactions themselves can
cause adverse effects. When a nanomedicine is administered in the body, it will
encounter a vast range of biological components, such as proteins, membranes,
DNA and organelles, and several nano-bio interfaces are established. Interactions
at the interface lead to various processes such as formation of protein coronas,
particle wrapping at the cell membrane, endocytosis and intracellular biocatalysis,
all which can have possible bioadverse outcomes. [13] For instance, nanoparticles
taken up via some endocytic pathways may elicit an immune response. [68] The
nature of the interface is influenced by nanoparticle characteristics including size,
shape, surface area, surface charge and hydrophobicity, which thereby also will be
determining factors affecting nanoparticle cytotoxicity.
The first step towards understanding how the body will react to administered
polymeric nanoparticles will nearly always rely on in vitro cytotoxicity studies. In
the majority of published articles investigating nanoparticle toxicity, cell viability
after exposure is measured by colorimetric methods. [64] These assays detect cell
death by changes in either metabolic activities or cell membrane permeability. One
method that relies on the former is the alamarBlue R© cell viability assay. This assay
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has incorporated a growth indicator, resazurin [69], which is reduced to resorufin
by innate metabolic activity, meaning that continued growth maintains a reduced
environment, while inhibition of growth results in an oxidized environment. [70]
Detection of this difference in redox state is possible since resazurin changes from
its oxidized, non-fluorescent, blue form to its reduced form, which is fluorescent and
red in color. As mentioned in the beginning of this section, the outcome of cellular
toxicity may not only be cell death. To complement the nanoparticle toxicity
studies described above it is also necessary to investigate possible inflammatory
and genotoxic responses.
2.2.2 Preparation of polymeric nanoparticles by the miniemulsion
process
Various methods for preparing polymeric nanoparticles have been developed. The-
se methods are classified into two main categories, depending on whether the pro-
cess requires a polymerization reaction or if it is achieved directly from a macro-
molecule or pre-formed polymer. [52] The choice of preparation process is depen-
dent on the polymer, but also on which substances it should be loaded with, its
site of action and therapy regime. [55]
One example of a highly versatile method for preparation of polymeric nanopar-
ticles that requires a polymerization reaction, is the miniemulsion process. A
miniemulsion is a relatively stable emulsion of small droplets dispersed in a contin-
uous phase. The droplets have a narrow size distribution and are usually between
20 and 200 nm in diameter. [71] To obtain the nanodroplets, high shear forces
with ultrasound or high pressure homogenization are applied on a mixture of two
immiscible fluids. The size of the final miniemulsion droplets is mainly dependent
on the type and amount of emulsifier used in the system. [72]
Preparation of nanoparticles with hydrophobic cores is performed by a direct
miniemulsion process, where a mixture of monomer, co-stabilizer and the agent to
be encapsulated is dispersed in an aqueous solution containing surfactant. Upon
intense shearing of the mixture, monomer droplets stabilized by the surfactant are
formed in the aqueous phase. The co-stabilizer will act as an osmotic pressure agent
within the droplets and prevent them from coalescing. [73] After the miniemulsion
is made, polymerization of the monomer occurs at the interface leading to forma-
tion of solid polymeric particles. One important feature with the miniemulsion
process is that the droplets act as nanoreactors, such that the size and content
of the resulting nanoparticles are almost identical to the droplets in the initial
emulsion. The polymerization reaction can either be triggered by addition of an
initiator or by initiator already present in the aqueous solution. Various types of
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polymerization reactions are used, including radical, anionic, cationic and enzyme
catalyzed polymerization. In figure 2.5 an overview of the miniemulsion process is
shown.
The main advantage with preparation of polymeric nanoparticles by the miniemul-
sion method is the possibility of simultaneous encapsulation of relevant hydropho-
bic drugs, contrast agents and fluorescent markers in a one-step process. In addi-
tion, surface functionalities, like PEGylation and targeting ligands, can be added
by co-polymerization such that further modifications are not needed. A summary
of the pros and cons with the miniemulsion process is displayed in table 2.6.
Figure 2.5: Schematics of the miniemulsion process for preparation of polymeric nanopar-
ticles. A miniemulsion is created by applying high shear forces on a mixture of an oil and
water phase, followed by the initiation of polymerization to form solid particles. Figure
from Y´rr Mørch, SINTEF Materials and Chemistry.
Table 2.6: Pros and cons with preparation of polymeric nanoparticles by the miniemul-
sion process. Provided by Ruth Schmid, SINTEF Materials and Chemistry.
Advantages Disadvantages
• One-step and low cost process
• Easy up-scaling to industrial scale
• Compatible with a wide range of
polymers
• High loading with active substance,
possible to encapsulate several
substances in one step
• No need for further modification
steps to add surface functionalization
• High shear forces necessary
• Residual surfactant, monomer
and/or stabilizer in the final product
• Unwanted chemical reactions
between active substance and
monomer may occur before or during
polymerization
• Lack of control of molecular weight
and polydispersity of the polymer
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2.3 Nanomedicines in cancer therapy
Cancer treatment is one of the most important fields for research on nanomedicines,
motivated by how chemotherapy is limited by systemic toxicity and poor bioavail-
ability of drugs at the tumor site. Chemotherapeutic agents tend to have rapid
degradation rates or they are quickly excreted, and because of poor distribution
they often fail to localize to the tumor. [74] In fact, only 0.1% of administered
anticancer drugs are able to reach the diseased area [75], resulting in remaining
agent being delivered where it is not required, possibly creating adverse effects in
healthy tissue.
Attempts to enhance the biodistribution of anticancer drugs, reduce free drug tox-
icity and favor tumor accumulation are done by designing drug delivery systems
exploiting nanocarriers. [25] By associating chemotherapeutic drugs with nanocar-
riers, the toxic side effects can be significantly reduced when compared to free drug.
Increasing the bioavailability and achieving homogeneous distribution of drugs at
the tumor site still remain a major challenge. Tumor tissue and normal tissue have
different physiology, giving rise to a set of transport barriers. Drug delivery to tu-
mors is therefore compromised, and to avoid heterogeneous distribution of drugs,
these physiological barriers need to be overcome. In addition, to further increase
bioavailability of the drug, different strategies for targeting of nanomedicines to
tumors have been evaluated.
2.3.1 Physiological barriers to drug delivery in tumor tissue
The transport of a therapeutic agent from systemic circulation to tumor cells
depends on the process of vascular, transvascular and interstitial transport. In
other words, a nanomedicine must first flow to different regions of the tumor
through the vascular network, then cross the vessel wall and at last try to reach
the target cells by penetrating the tumor interstitium. Because of differences in
structure between normal and cancerous tissue, physiological barriers that limit
both the rate and extent of drug delivery to target cells are introduced. The major
contributions to the drug delivery barriers in tumor tissue are abnormal blood
vessel network, accumulated solid stress, elevated interstitial fluid pressure and a
dense interstitial structure. [76] It is important to note that these are inherent
properties of the tissue, and both the existence and contribution from each might
vary between cancer types.
In order for a tumor to grow beyond 1-2 mm in size, the tumor switches to an
angiogenic phenotype to provide sufficient delivery of oxygen and nutrients for
further growth. [77] Cancer cells therefore secrete proangiogenic factors to the sur-
Theory 17
rounding tissue, leading to growth of new blood vessels that connect the tumor to
the body’s vascular system. Since these factors are overproduced, the growth hap-
pens rapidly, resulting in an immature vasculature with a highly irregular structure
and vessels that remain leaky and tortuous. The high vessel tortuosity contributes
to an elevated viscous and geometric resistance, while the structure of the vessel
network causes heterogeneous blood flow through the tumor. Both characteristics
compromise tumor blood flow, and leave the average velocity of red blood cells
up to an order of magnitude lower than in normal tissue. [78] Consequently, the
abnormal blood vessel network affects the movement of nanomedicines through
the vasculature and into different regions of the tumor, resulting in nonuniform
drug delivery.
Solid stress in the tumor is induced when cells proliferate in an uncontrollable
manner in a constricted space, and results in compression of blood and lymphatic
vessels. [79, 80] When blood vessels are compressed, or even collapsed, blood flow
to the tumor is restricted and may leave some regions of the tumor tissue unper-
fused. The presence of unperfused regions lead to a hypoxic, acidic and necrotic
tumor microenvironment, which can further contribute to drug resistance and
tumor progression. [76] Because of compression of lymphatic vessels, lymphatic
drainage from the tissue is not working properly and fluid will accumulate in the
interstitial space, causing higher interstitial fluid pressure than in normal tissue.
The leaky blood vessels will further contribute to the elevated interstitial fluid
pressure. Discontinuities in endothelial cells lining the vessel wall cause tumor
vessels to be hyperpermeable, and more fluids and plasma macromolecules will
leak into the tumor interstitium. [81] Combined with the nonfunctional lymphatic
drainage, this results in an elevated interstitial fluid pressure which approaches
the value of the microvascular pressure. In normal tissue, the transvascular and
interstitial transport are driven by diffusion and convection. The main driving
force for convective transport is the transvascular and interstitial pressure gradi-
ents. In tumor tissue these gradients will be approximately zero, leaving diffusion
the main transport mechanism of nanomedicines crossing the vessel wall and pen-
etrating the tumor interstitial space. Transvascular and interstitial transport are
thereby hindered by the elevated interstitial fluid pressure, causing transport of
nanomedicines to be limited by diffusion, resulting in poor distribution and short
penetration range of the therapeutic agent.
The interstitial matrix is a network comprising of a variety of proteins and polysac-
charides. In a tumor, where the cellular density is high and solid stress is accumu-
lated, the interstitial matrix is compressed into a dense and tortuous network. [82]
Transport of a nanoparticle system within the interstitial matrix is primarily gov-
erned by diffusion, and the movement is affected by its size together with the
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viscosity of the interstitial fluid. Because diffusion is size dependent, smaller nano-
medicines have an advantage when compared to larger ones, since they are less
hindered by interactions with the interstitial matrix and may achieve deeper tu-
mor penetration. In conclusion, the dense structure of the interstitial matrix causes
barriers to nanomedicine movement in tumors and results in a heterogeneous dis-
tribution with nanoparticles concentrated in perivascular regions.
2.3.2 Passive targeting of nanomedicines to tumors
When delivering drugs with nanocarriers to tumors, one beneficiary aspect with
tumor physiology can be found. The leaky blood vessels, with abnormally wide
gaps between endothelial cells, allow extravasation of materials with a certain size,
typically in the range of nanomedicines. Furthermore, solid tumors are unable to
eliminate extravasated nanoparticles since the lack of functional lymphatics leads
to fluid retention. The combination of these two physiological characteristics give
rise to the enhanced permeability and retention (EPR) effect for macromolecules
in solid tumors [84], allowing for long-circulating nanomedicines to accumulate
in tumors over time. (Figure 2.6A) Since this way of guiding nanomedicines to
tumors only rely on the pathophysiological state of cancerous tissue, it is generally
referred to as passive targeting. Passive targeting is arguably the most important
strategy for targeting nanoparticle systems to tumors. [85]
The EPR effect has proven to passively guide nanomedicines to solid tumors. In
fact, the clinical success Doxil R©/Caelyx R© relies on passive accumulation at its
target site. Despite this, it must not be disregarded that the EPR effect is a
phenomenon which varies significantly from tumor model to tumor model, from
patient to patient, and even within a single tumor. [86, 87] In some cases, parti-
cles as large as 200 nm are able to extravasate, whereas in others not even small
molecules are able to enter the interstitium. [88] These variations are mainly caused
by heterogeneities of vascular permeability; some vessel areas can have intact en-
dothelial lining or the vascular leakiness can be compromised by the presence of a
dense perivascular lining.
2.3.3 Active targeting of nanomedicines to tumor tissue
Opposed to passive targeting of nanomedicines, active targeting can be achieved
by conjugating ligands to the surface of a nanocarrier that promotes binding to
specific cell surface receptors expressed at the target site. Nanoparticle systems
that are actively targeted to cancer cells are made with the motivation of improv-
ing target cell recognition and enhancing cellular uptake. The general idea is that
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Figure 2.6: Overview of different targeting strategies for delivery of drugs to tumors. A:
Passive targeting of nanomedicines to tumors relies on the enhanced permeability and
retention effect. B: Active targeting to cancer cells intends to improve cellular uptake of
the nanomedicine. C: Active targeting to endothelial cells aims to reduce blood supply
to tumors and thereby deprive the cells from oxygen and nutrients. D: Targeting to
tumors by an externally applied stimulus to trigger drug release from stimuli-sensitive
nanomedicines. Figure adapted from reference [83].
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the EPR effect will be responsible for tumor accumulation, while the targeting
ligands increase the specificity of the nanoparticle system. (Figure 2.6B) Ideally,
interactions between the ligand-bearing nanocarrier and receptors at the cell mem-
brane will cause the nanoparticle to be internalized through the same endocytosis
pathway as the ligand alone. A large variety of substances can be used as targeting
ligands, including antibodies and other proteins, lipoproteins, hormones, charged
molecules, and saccharides. [89] It is important that the ligand binds selectively to
the desired receptor, and the target tissue should overexpress the surface marker
in order to maximize specificity of the interaction.
In recent years, significant progress has been made with active targeting strategies
at the preclinical level, although no actively targeted nanomedicines have been
approved for clinical use, and only very few are in clinical trials. [85] The con-
straints on cancer cell targeted nanomedicines are believed to mainly be caused
by two factors. First, after the nanomedicine has crossed the blood vessel wall, it
needs to overcome additional physiological barriers before it can reach and bind
tumor cells. (Barriers to interstitial transport, see section 2.3.1) Second, attach-
ment of a targeting ligand on the surface of a nanocarrier can cause increased
immunogenicity and unspecific protein adsorption, thus lowering the amount of
nanomedicines passively accumulated in the tumor. As it seems today, the biggest
advantage with nanomedicines actively targeted to cancer cells, over those that
only rely on passive targeting, is that they are much more efficiently internalized
into cells. This property can be particularly useful for drugs that need to be
delivered intracellularly.
An active targeting approach that circumvents the barriers to interstitial transport,
is based on active targeting to angiogenic endothelial cells rather than cancer cells
themselves. [90] Such a targeting strategy aims to increase drug delivery to the tu-
mor endothelium, thereby depriving tumors of oxygen and nutrients. (Figure 2.6C)
Since nanomedicines targeted to the tumor vasculature are not dependent on ex-
travasation and penetration through the dense interstitium, and because of their
frequent encounter with their target receptors, it is claimed that endothelial cell
targeted nanomedicines possess more potential for improving antitumor efficacy
than cancer cell targeted nanomedicines. [88]
2.3.4 Targeting to tumors by triggered drug release from
nanomedicines
One of the fastest growing areas of research on nanomedicine targeting is the
design of nanocarriers that selectively release their contents upon exposure of an
external stimulus. (Figure 2.6D) The idea behind such nanoparticle systems is
Theory 21
that when certain stimuli is applied to the pathological area from outside of the
body, the properties of the nanoformulation is changed, allowing for enhanced or
controlled drug release. Examples of externally provided stimuli can be heat, light,
ultrasound and magnetic fields. In theory, the stimuli-responsive nanosystems hold
significant clinical potential, since they are designed to only release the therapeutic
agent upon application of spatially confined triggers, thereby maximizing drug
release in tumor tissue and at the same time protecting healthy tissues against
damage. [88] A challenge with stimuli-responsive nanomedicines is to make their
formulation really specific to the external stimulus. Moreover, to provide triggered
drug release, the location of the tumor must be known, meaning this strategy is
not ideal for the treatment of metastases.
Ultrasound can be used in different ways for triggered drug delivery. It can re-
lease encapsulated drugs from a nanocarrier, but it can also be used to overcome
existing barriers in tumor tissue by modification of the tumor microenvironment.
When energy is deposited in tissue from focused ultrasound, three main biologi-
cal effects occur: hyperthermia, radiation forces and acoustic cavitation. [91] The
generation of heat from applied ultrasound can trigger drug release from tempera-
ture sensitive nanomedicines. [92] An example of such carriers are the temperature
sensitive liposomes developed by Needham, Dewhirst and co-workers. [93] These
liposomes loaded with doxorubicin (patented under the trade name ThermoDox R©)
are in clinical trials for different indications, where one planned study will evaluate
High Intensity Focused Ultrasound in combination with ThermoDox R© for treat-
ment of prostate cancer metastases to bone. (Clinical trial ID: NCT01640847)
Local heating of tissue can have additional beneficial effects; increased blood flow,
vascular permeability and diffusion can facilitate both vascular and transvascular
transport, resulting in enhanced tumor accumulation of nanoparticles.
Nonthermal biological effects of ultrasound can generate radiation forces that im-
prove convection of nanomedicines and therapeutic agents within the tumor in-
terstitium, and thereby help with overcoming the diffusion problem associated
with the dense tumor interstitial matrix. The use of microbubbles as ultrasound
contrast agents, either in combination with drug delivery systems or as a multi-
functional system (described in section 2.1.3), may induce cavitation-based effects
connected with bubble oscillations. Acoustic cavitation can act positively on the
transport of drugs in a tumor, and also cause a local increase in cell membrane
permeability. Microstreaming will occur around bubbles undergoing stable cav-
itation, which can increase the speed of convective transport of drugs by orders
of magnitude compared to diffusive transport alone [94] Collapse of an oscillating
bubble following inertial cavitation emits high pressure microjets to the surround-
ings. These microjets can inflict shear stresses on nearby cells which again will
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increase membrane permeability by creating transient pores in the cell membrane,
a process termed sonoporation. It has been reported that sonoporation allows for
transmembrane delivery and cellular uptake of macromolecules between 10 kDa
and 3 MDa. [95] To summarize, the combined biological effects of ultrasound on
cancer cells, endothelial cells and the tumor interstitial matrix can potentiate local-
ized drug delivery by facilitating vascular, transvascular and interstitial transport
of nanomedicines and drugs, as wells as by aiding their entry into cells.
2.4 Cellular uptake and trafficking of nanoparticles
Nanocarriers offer unique possibilities to cross cellular barriers in order to facil-
itate the delivery of therapeutic agents. Various internalization pathways are
available for nanoparticle uptake in mammalian cells. These processes are col-
lectively termed endocytosis. Generally, endocytosis can be divided into two main
categories: phagocytosis and pinocytosis. Phagocytosis is the uptake of partic-
ulate matter and occurs primarily in specialized cells such as macrophages and
neutrophils. [96] Pinocytosis on the other hand, occurs in all cells and is the
internalization of fluids and solutes. It can be divided into macropinocytosis,
clathrin-dependent endocytosis, caveolae-mediated endocytosis and mechanisms
independent of both clathrin and caveolae. For drug delivery to cancer cells, it
is most relevant to look into the pinocytosis pathways. Figure 2.7 illustrates the
different endocytosis mechanisms mentioned above.
Figure 2.7: An illustration showing the principal internalization pathways in mammalian
cells, divided into phagocytosis and pinocytosis. Pinocytosis is further subdivided into
macropinocytosis, clathrin-dependent endocytosis, caveolae-mediated endocytosis, and
other mechanisms independent on both clathrin and caveolae. Figure adapted from
reference [97].
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Endocytosis is a form of transport where extracellular material is taken up in an
energy dependent manner. A nanoparticle located at the exterior of a cell can in-
teract with the plasma membrane. These interactions can lead to the nanoparticle
being endocytosed by the cell. First, the cargo is enclosed in membrane invagina-
tions by infolding of the plasma membrane, followed by pinching off of a membrane
bound vesicle or vacuole. Endocytic vesicles fuse with each other, or an already
existing endosomal compartment to form an early endosome. In these cellular
structures sorting of the cargo is carried out. The cargo can then follow different
routes. [98, 99, 100] Material destined to be recycled to the extracellular space
is either removed directly back to the cell surface, or pass through a recycling
endosome for further processing. Trafficking between endosomes and the Golgi
apparatus connects the endocytic and secretory pathways, and provide delivery
of endocytosed material to various intracellular compartments. In the process of
endosome maturation (the transition from early to late endosome), the pH in the
compartment decreases and further fusion with endocytic vesicles is prevented.
Late endosomes can fuse with or mature into a lysosome, where the content is
degraded. A great portion of internalized cargo remains in the late endosomes to
follow this degradation route. Figure 2.8 summarizes the major trafficking path-
ways for endocytosed material.
The formation of the endocytic vesicle and further intracellular trafficking differs
depending on which endocytic pathway involved in the internalization process.
Table 2.7 is provided to give a short summary of the vesicle morphology and
implicated proteins in the different pinocytosis mechanisms.
Table 2.7: Some known characteristics with the pinocytosis pathways described in the
text. Table adapted from reference [101].
Endocytosis pathway Morphology Implicated proteins
Macropinocytosis Highly ruﬄed Actin, Rac1
Clathrin-mediated Vesicular Clathrin, Dynamin, Rab5
Caveolae-mediated Vesicular or
tubovesicular
Caveolins, some evidence of
dynamin dependence.
Clathrin and caveolae
independent
Vesicular or
tubular
Different mechanisms dependent on
Arf6, flotilin, Cdc42 and RhoA re-
spectively. Majority of pathways
seem to be dynamin independent.
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Figure 2.8: A schematic diagram of the principle organelles and pathways involved in
endocytosis and intracellular transport of nanoparticles. Trafficking between endosomes
and the Golgi apparatus links the pathways of endocytosis and secretion. Figure adapted
from reference [98].
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Nanoparticles can employ multiple pathways for cellular entry. Investigation of
the cellular uptake and trafficking of nanocarriers suggests that this process is
highly dependent on the particles’ physicochemical characteristics. [102] Properties
such as size, shape, charge and hydrophobicity are ascertained to influence the
endocytosis of nanomaterials. In addition, the endocytic machinery present in a
cell varies between cell types, meaning that rate and mechanism of uptake also is
cell-line dependent. [103] Several review articles [14, 102, 103, 104] are available
that summarize published data on nanoparticle uptake and transport in cells, but
given the diversity of nanoparticles and cell types utilized in research today it is
difficult to make any conclusions regarding common factors. In order to develop
efficient drug delivery systems based on nanocarriers, it is necessary to increase
our understanding on how they are internalized and distributed in cells, and the
mentioned review articles reveal that thorough studies are needed in each situation.
2.5 Drug release from biodegradable nanoparticles
Upon arrival at the target site, a nanocarrier should deliver its contents in an
efficient manner to achieve sufficient therapeutic response. Depending if the ther-
apeutic agent is covalently bound or encapsulated within the nanoparticle, dif-
ferent release strategies apply. Covalent drug delivery requires direct breaking of
the chemical bond between the drug and the nanocarrier, whereas non-covalently
bound drugs do not require additional external stimuli to be released. [105] Since
pharmacological targets often are located intracellularly [11], many drugs require
uptake in cells for the delivery to be successful. This is possible either by extracel-
lular release followed by drug diffusion across the cell membrane, or the nanocarrier
must enter the cell by endocytosis before drug release. The release of therapeutic
agent outside cells is more efficient when using hydrophobic drugs, since it is the
partition coefficient of a molecule that determines the diffusion rate across a lipid
bilayer. [106]
There are a number of possible methods for drug release from biodegradable
nanoparticles: [107, 108, 109]
1. Desorption of drug bound to the surface
2. Diffusion through the nanoparticle matrix
3. Nanoparticle matrix erosion
4. A combined erosion-diffusion process
It is proposed that several of the above mentioned processes can contribute to
the overall mechanism for drug release. First, a rapid initial release can stem
from weakly bound or adsorbed drug on the nanoparticle surface. Then, a slower,
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more controlled release can follow, which is attributed to nanoparticle degradation,
diffusion of the drug through the nanoparticle matrix, or both. This means that the
diffusion coefficient of the drug and the biodegradation rate of the nanoparticle are
determining factors of drug release. Consequently, if diffusion of a drug is faster
than matrix erosion, the mechanism of release is predominately controlled by a
diffusion process.
2.5.1 Nile red properties and its release mechanisms from
nanoparticles
The release and subsequent cellular uptake of a lipophilic probe can be used as a
tool to study the delivery of hydrophobic drugs from nanoparticles to cells. In this
project, the fluorescent probe nile red has been used for this purpose.
Nile red is a highly hydrophobic, benzophenoxazone fluorescent dye. It is intensely
fluorescent in all organic solvents, but efficiently quenched in aqueous solution. Nile
red has high affinity for intracellular lipid compartments [110], and depending on
what it is associated with, the excitation and emission maxima can vary over a
range of 60 nm. [111] The dye exhibits a blue shift of the fluorescent emission max-
ima which is proportional to the hydrophobicity of the environment. This means
that nile red associated with more hydrophobic compounds (e.g. intracellular
lipid-droplets) are more visible when cells are viewed for yellow-gold fluorescence,
than when cells are viewed for red fluorescence, where a diffuse general staining of
the cytoplasm (attributed to nile red associated with various cytosolic proteins)
becomes more apparent.
Haynes and Cho [112] proposed that transfer of nile red from hydrophobic nanopar-
ticles and into cells could occur through three processes:
1. By endocytosis
2. By probe dissociation from the particle and subsequent diffusion towards the
cell and over the plasma membrane
3. By partition of the probe upon particle collision with the cell membrane
Endocytosis is already presented in section 2.4, so further only the diffusion-based
drug delivery processes will be discussed. Both the diffusion dependent processes
rely on a hydrophobic release mechanism, in which the release is initiated when
the nanocarrier encounter an even more hydrophobic environment (such as a cell
membrane) into which the probe can diffuse. [105] For the second mechanism, the
dissociation of the probe from the particle and into the less hydrophobic envi-
ronment (not favorable process) will be rate-determining, whereas the rate of the
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third mechanism is determined by particle-membrane collisions. Hence, the second
mechanism is believed to be much slower than the collision-induced process.
Literature has provided evidence that different nanocarriers (polymeric nanoparti-
cles, liposomes and micelles) indeed can deliver their payloads mainly in a release-
or contact-mediated manner. [113, 114, 115, 116] These results implicate that the
release rate can be used to determine cellular drug content. In order for such a drug
delivery system to have clinical applications, the leakage of drugs during systemic
circulation must be minimized. In addition, it is important to assess how a drug
prefers the nanoparticle environment versus the biological microenvironment. [105]
2.6 Flow cytometry
Flow cytometry (FCM) is a quantitative technique used for analyzing objects in the
micrometer size range, such as cells. A liquid cell suspension is passed through a
laser beam and scattered light and fluorescence are detected. This information can
be used to obtain the physical and/or chemical characteristics of cells. Examples
of some FCM applications are cell cycle analysis, immunophenotyping, viability
measurements and identification of extra- or intracellular protein expression.
2.6.1 General principles of flow cytometry
As seen in figure 2.9, a flow cytometer’s main parts are a flow cell, a light source,
an optical system, light detectors and a data processing and operating unit. [117]
The cell suspension to be analyzed is first injected into the flow cell, where the
sample fluid is hydrodynamically focused into a thin stream by the surrounding
sheath fluid. Further into the fluidics system, the sample stream will intersect with
a laser beam placed orthogonal to the flow. The hydrodynamic focusing serves to
make cells flow in a single file, such that only one cell at the time are passing
the detection point. When cells in the stream pass through the sensing point,
light from the laser source interacts with each individual cell to produce scattering
and/or fluorescence. The generated photons hit a photodetector and this intensity
pulse is translated into a voltage pulse proportional to the total number of photons
that reached the detector. This voltage is then amplified by a series of linear or
logarithmic amplifiers, and converted into a digital signal that can be displayed
graphically by the data processing and operating unit. [117]
The optical response generated by interaction of a cell with the laser beam consists
of forward scattered and side scattered light. In addition, absorption either by
cellular components or by fluorochromes staining a cell, produces fluorescence
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Figure 2.9: Schematic diagram showing the setup and main components of a flow cy-
tometer. [117]
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signals shifted in wavelength from that of the exciting beam. [118] These detected
parameters provide information about the cells’ properties. The magnitude of
forward scattered, or low angle scattered light (0.5 to a few degrees), is nearly
proportional to the size of a cell. Side scattered, or highly scattered light (∼90◦),
is related to the granularity and internal structure of a cell. To measure other
cellular characteristics, the cell sample can be labeled with a fluorescent molecule.
Such fluorescent dyes can bind to specific molecules inside the cell or on the cell
surface, thus making it possible to detect certain cellular parameters. Since every
cell becomes equally illuminated at the detection point, proportionality between
fluorescence intensity and the measured parameter is assured.
One of the strengths with FCM is that excitation with several lasers of different
wavelengths are possible at the same time. Measurements of more than one cellular
parameter can then be performed simultaneously. By combining results from light-
scattering and fluorescence measurements on both stained and unstained cells, a
wide range of cellular parameters can be detected. Some of the cell characteristics
that can be determined are cell size, granularity of cytoplasm, cell shape, viability,
autofluorescence, and in addition cell components like DNA, surface receptors and
antigens. [119] Alternative techniques to measure many of these parameters exist,
but the real power of FCM lies in the ability to obtain information on how the
parameters are distributed and correlated in the cell population.
2.6.2 Data analysis of flow cytometry measurements
Data obtained during FCM measurements are analyzed by the flow cytometer soft-
ware and presented to the user graphically. Single parameter histograms plot the
fluorescence or light scatter intensity against number of cells. This gives informa-
tion about the intensity distribution of a particular parameter in the cell sample.
A population of cells that have high intensity of the desired property is termed a
positive dataset. Figure 2.10 shows a typical histogram with a negative (autoflu-
orescence) and positive population. To obtain further information about how the
parameters are distributed in the sample, two single parameter histograms can be
combined to yield a two-dimensional dot-plot.
From a single parameter histogram the software allows you to obtain the median
fluorescence intensity (MFI) of the sample. The median is the fluorescence value
below which 50% of the events are found, and for logarithmic data this num-
ber gives a better estimation of the central tendency of a population than the
mean. [120] An observed shift in fluorescence intensity can then be quantified by
reporting the relative MFI values compared to a control. The percentage of posi-
tive cells can also be estimated from the negative cell population. A marker that
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Figure 2.10: A typical single parameter histogram obtained in FCM analysis. [117]
The histogram shows the fluorescence intensity of the unstained population (autofluo-
rescence) and the stained sample. Thus, the left peak represents a negative dataset,
whereas the right represents a positive. Number of events (counts) are displayed on
a linear scale on the y-axis, while the x-axis represents the fluorescence intensity on a
logarithmic scale.
Figure 2.11: A typical dot plot of forward scatter versus side scatter obtained in a
FCM analysis. The plot shows the distribution of cells in the sample based on size
and granularity. A gated population is set to avoid cell debris and cell clusters. The
forward scatter signal is plotted on a linear scale and the side scatter signal is plotted
on a logarithmic scale.
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includes a small percentage of the control sample is set, and any intensity greater
than this in the stained samples are defined as positive.
An important feature with FCM data analysis is the gating option. Gating is
the selection of a specific set of cells for further analysis and exclusion of data
from unwanted events. For instance a dot plot with forward scatter against side
scatter signal shows the distribution of cells based on size and granularity. This
information can be used to make a gate to eliminate cell debris, fragments and cell
clusters, such that subsequent analysis only is based on data from whole, single
cells. Figure 2.11 illustrates such a gating example.
2.7 Confocal laser scanning microscopy
Confocal laser scanning microscopy (CLSM) is a technique routinely used for imag-
ing of fluorescently labeled biological specimens. The sample is illuminated by a
focused scanning laser beam, and out-of-focus light is rejected from reaching the
detector by a confocal aperture. This basic principle of confocal imaging provides
images with enhanced contrast compared to conventional widefield optical systems.
Examples of typical information that can be obtained by investigation with CLSM
is whether the fluorescent signal originates from the membrane or the cytosol of a
cell, if different fluorescent signals are co-localized within the same organelle and
the three-dimensional fluorescence distribution in the specimen. [121]
The confocal laser scanning microscope is an integrated system consisting of a
fluorescence microscope, multiple laser light sources, a confocal scan head with
optical and electronic equipment, a monitor for display, and software for acquiring,
processing and analyzing images. [121] Figure 2.12 shows the optical principle of
a confocal laser scanning microscope. First, a coherent laser beam is reflected by
a dichromatic mirror and focused onto the sample by an objective lens. When
the laser beam interacts with the specimen, fluorescent photons are generated.
The fluorescent photons originating from the excited point are then collected by
the same objective onto a pinhole aperture placed in front of a photodetector.
This pinhole aperture is situated in the conjugate plane of the focused sample
plane, thereby largely excluding fluorescence signals from objects above and below
the focal plane. Consequently, all out-of-focus background is removed and only
photons originating from the plane in focus will contribute to the image. The
intensity of the fluorescent photons incident on the photodetector are translated
into a voltage signal, and further digitalized and displayed on the monitor. Various
filters and lasers can be used to obtain multichannel images such that detection of
more than one fluorescent probe is possible at the same time.
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To generate an entire image, the laser beam is scanned across a defined horizontal
plane of the specimen in a raster pattern. In this way, CLSM allows investigation of
thin optical sections within the sample. The thickness of the optical sections can be
adjusted by varying the size of the pinhole aperture. Additionally, optical sections
from selected depths in the sample can be scanned and collected to generate a
three-dimensional image. By changing the scan speed of the laser, the contrast
and quality of the image can be modified. [122] Slower scan speed gives superior
image quality, but requires longer acquisition time.
Figure 2.12: Schematic diagram showing the optical setup of a confocal laser scanning
microscope.
3 Materials and Methods
3.1 Nanoparticles
Colleagues at SINTEF Materials and Chemistry have synthesized and character-
ized the polymeric poly(alkyl cyanoacrylate) nanoparticles used in all experiments.
An overview of the physicochemical properties of all batches is displayed in ta-
ble 3.1. The given size and zeta (ζ) potentials were measured by dynamic light
scattering in a Malvern Zetasizer Nanoseries.
3.1.1 Synthesis of nanoparticles
The nanoparticles are produced by a direct miniemulsion process. This process
involves mixture of an acidic aqueous phase containing surfactant and initiator,
with an oil phase containing monomers and co-stabilizer. All batches are pro-
duced with poly(butyl cyanoacrylate) (PBCA) as the monomer, except 89 which
consists of poly(octyl cyanoacrylate) (POCA). Upon sonication of the two phases,
a miniemulsion is formed. The surfactant used to stabilize the emulsion is sodium
dodecyl sulfate (SDS), except for particle batch 71B and 72 where TWEEN 80 is
used. Anionic polymerization of the monomer droplets is initiated by addition of
PEG to the emulsion, due to the presence of amine groups on the PEG chains,
resulting in PEGylated nanoparticles. After polymerization, the surfactant is re-
dundant, and is removed by dialysis in water. More details on the miniemulsion
process can be found in section 2.2.2.
Batch 44 is synthesized at an earlier time than the rest, and differs at some points.
It is produced with hexadecane as a co-stabilizer, whereas all other batches are
produced with Miglyol 810N. In addition, the PBCA polymer is cross-linked in
the particle.
3.1.2 Fluorescent labeling of nanoparticles
To be able to detect the nanoparticles in FCM and CLSM, they are labeled with a
fluorescent marker. These probes are associated with the particles in various ways.
Nile red and fluorescein acrylate is encapsulated in the hydrophobic core of the
particle, meaning they are mixed with the oil phase when the emulsion is formed.
The difference between the two fluorescein acrylate batches is that in batch 69,
fluorescein acrylate was dissolved in oil approximately 12 hours before preparation
since difficulties with dissolving it in the oil phase was experienced during synthesis
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of batch 68. Fluoresceinamine is coupled to the surface of the particle. In batch
66, the amine groups on fluoresceinamine are bound to acid groups on the particle
surface. For batch 82 and 83, fluoresceinamine is coupled directly onto the surface
through the amine groups, which react with the monomer and initiate polymer-
ization. In 82, fluoresceinamine was added to the nanoemulsion before addition of
PEG, whereas in 83 fluoresceinamine was added together with the PEG chains. In
the dialysis process, fluorescein molecules that became redundant during synthesis
will be removed. However, this does not apply for nile red, as it is hydrophobic
and will not diffuse as readily into the water phase. Nanoparticle 44 is added 5
times less nile red during synthesis than the other nile red loaded particles.
Measurements show that nile red associated with poly(alkyl cyanoacrylate) parti-
cles has an excitation and emission maximum at 540 nm and 600 nm respectively.
Fluorescein derivatives have a maximum absorption around 495 nm, and an emis-
sion maximum at approximately 520 nm.
3.1.3 PEGylation of nanoparticles
All the nanoparticles are PEGylated, but with chains of different composition
and length. Table 3.2 displays the types of PEGs used and a comparison of
their approximate molecular weights and number of ethylene oxide units per chain
(NEOperPEG). The chemical structures of all chains can be found in appendix A.
TWEEN 80 serves not only to provide a hydrophilic coating of the nanoparti-
cles, but also as a surfactant to stabilize the miniemulsion. The presence of PEG
was confirmed by nuclear magnetic resonance (NMR) measurements performed by
postdoc Andreas A˚slund, in all batches except 68 and 79, where measurements
were not performed.
Table 3.2: Summary of approximate molecular weight and number of ethylene oxide
units for the different PEG chains used to coat the nanoparticles.
Name PEG type Molecular
weight (Da)
NEOperPEG
Amino-PEG
Methoxypolyethylene
glycol amine
750 16
2000 45
5000 114
Jeffamine Polyetheramine
1000 19
2000 29
OH-PEG-NH2 Aminopolyethylene glycol 3400 77
TWEEN 80 Polyethylene sorbitol ester 1300 20
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3.1.4 Estimation of average PEG chain density on the nanoparticles
Estimation of the average PEG chain density (ρPEG) on the particle surface was
done from NMR measurements. The samples were centrifuged and washed before
analysis, in order to remove PEG chains in the solution that was not associated
with the particle surface. It was assumed that all measured PEG were on the
surface of the particles, and the surface density was defined as the ratio between
the total number of PEG chains (NPEG) and the nanoparticle surface area (SNP ):
ρPEG =
NPEG
SNP
(1)
The surface area of one nanoparticle is given simply by SNP = 4pir
2, where r is
the particle radius. To estimate NPEG it was necessary to use the NMR data.
These measurements give a ratio between the amount of PEG and polymer in the
sample:
NMR-ratio =
nPEG
npolymer
(2)
It was further assumed that this ratio also represented the relation between PEG
and polymer in one nanoparticle. When placed in a magnetic field, NMR active
nuclei absorb electromagnetic radiation. Since the alkyl(cyanoacrylate) monomer
contains only one such nuclei, whereas a PEG chain has one per ethylene oxide
unit, the NMR-ratio was divided by the number of ethylene oxide units per PEG
chain (NEOperPEG) to give:
NMR-ratio
NEOperPEG
=
nEO
nNP
(3)
The number of mole in one nanoparticle (nNP ) was then estimated by assuming
that the particle only consists of polymer:
nNP =
mNP
MWpolymer
(4)
where the mass of one nanoparticle (mNP ) was calculated by assuming a particle
density equal to water. Following, the number of mole ethylene oxide (nEO) was
resolved by using equation 3. This value was multiplied by Avogadro’s number to
yield the number of ethylene oxide units per particle (NEO). NPEG could then be
estimated by dividing NEO by the number of ethylene oxide units for the respective
PEG chains:
NPEG =
NEO
NEOperPEG
(5)
The PEG density estimation was only done on particles coated with the linear
PEG chains, i.e. Amino-PEG, Jeffamine and OH-PEG-NH2.
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From the estimated surface density data it was possible to determine the area
occupied by one PEG chain on a particle:
APEG =
SNP
NPEG
(6)
If the surface area covered by one PEG chain is assumed to be a circle, the average
distance between two neighboring PEG chains (D) equals the diameter of this
circle:
D = 2
√
APEG
pi
(7)
3.1.5 Estimation of PEG surface conformation
Using the model published by de Gennes et al. [123], the PEG surface conformation
was determined. If the distance between PEG chains on the surface (D) is larger
than the relative polymer size, or Flory radius (RF ), all PEG chains are expected
to be present in the mushroom regime, whereas with D smaller than RF the PEG
chains are found in a brush conformation. For cases where D is comparable to
RF , a so called mushroom-to-brush transition regime exists. The Flory radius of
a polymer is given by:
RF = aN
3/5 (8)
where a is the monomer length (0.35 nm for PEG [124, 125]) and N is the number
of monomer units in the polymer (NEOperPEG for the PEG chains).
3.2 Cell cultivation
PC3 (Prostatic Adenocarcinoma) cells with American Type Culture Collection
number CRL-1435 were cultured in monolayer in plastic flasks (nunc) and incu-
bated at 37◦C and 5% CO2. The cell culture medium was Dulbecco’s modified
eagle medium (Gibco Invitrogen) supplemented with 10% fetal bovine serum (FBS,
Sigma Aldrich). Passaging to a new flask was done when the cells were approach-
ing confluency. First, the old growth medium was removed, followed by washing
with phosphate buffered saline (PBS, Sigma). After PBS removal, trypsin/EDTA
solution (0.25%/0.2%, Sigma Aldrich) was added before incubation at 37◦C for
2-3 minutes, allowing the cells to detach. To stop the effect of the enzymes in
the trypsin solution, growth medium was added. Following, the cell suspension
was centrifuged at 1500 rpm for 5 minutes. Prior to centrifugation, a few drops
of cell suspension was added to a Bu¨rker chamber. The chamber was observed
in a transmission light microscope and the cells were counted to estimate the cell
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concentration. After spin down, the supernatant was discarded and the cell pellet
was resuspended in medium. As a last step, an appropriate number of cells were
passaged to a new flask.
3.3 Studies of nanoparticle uptake in cells with flow
cytometry
FCM analyses were done to investigate the uptake of different nanoparticles in
cells. For these experiments, PC3 cells were seeded in 25 cm2 plastic flasks. In
each flask, 1×106 cells/5 ml medium were allowed to adhere and grow for 48 hours
before the experiment, or 2× 106 cells/5 ml medium 24 hours in advance.
3.3.1 Incubation of cells with nanoparticles
On the day of the experiment, the old medium was discarded and 5 ml of nano-
particle-medium solution, with a concentration of 20 µg/ml, was added to each
flask. This value was chosen since previous studies showed minimal reduction in
viability of PC3 cells after addition of similar PBCA nanoparticles at this concen-
tration. [126] Incubation was done at 37◦C and 5% CO2 for 3 hours. To assess
whether the uptake was energy dependent or not, cells with nanoparticles were
also incubated at 4◦C. After incubation, the nanoparticle-medium solution was
removed, and the cells were rinsed with 3 ml of PBS, 3 times per flask. The cells
were then detached by adding 1 ml trypsin/EDTA solution and kept at 37◦C for
2-3 minutes. To stop the trypsination process, 7 ml growth medium was added.
The added medium was cold in order to stop the cells’ metabolism before FCM
analysis. Subsequently, the resulting cell suspension from one flask was trans-
ferred to 4 centrifuge tubes, 2 ml in each. 3 of these tubes were then centrifuged
at 1000 rpm for 3 minutes, 1, 2 and 3 times respectively. The purpose was to
assess whether more extensive washing of the samples would affect the fluores-
cence intensity by collecting one sample from each step in the washing procedure.
One flask incubated with nanoparticles would therefore yield 4 samples for FCM
analyses:
• 3 times rinsed with PBS
• 3 times rinsed with PBS, centrifuged at 1000 rpm for 3 minutes
• 3 times rinsed with PBS, centrifuged 2 times at 1000 rpm for 3 minutes
• 3 times rinsed with PBS, centrifuged 3 times at 1000 rpm for 3 minutes
Control samples with no nanoparticles added were also analyzed.
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Awaiting FCM analyses, the samples were kept dark to prevent photobleaching and
on ice to inhibit further energy dependent uptake. The analyses were performed
as soon as sample preparation was finalized, in order to minimize possible diffusion
of the fluorescent marker. Approximately 1 ml of cell suspension was transferred
to each FCM tube.
3.3.2 Flow cytometry setup
Analyses of samples were performed in a Gallios flow cytometer (Beckman Coul-
ter). A total of 10.000 cells were counted from each sample, or the data collection
was aborted after analyzing the sample for 300 seconds. By plotting the forward
scatter signal against the side scatter signal in a dot plot, a collection gate was
established to exclude cell debris and clusters. From these events, a single pa-
rameter histogram of counts versus fluorescence intensity was obtained. Control
samples were analyzed to exclude the autofluorescence contribution. In the his-
togram described above, when analyzing untreated cells, the peak should be within
the first decade on the x-axis. All events with higher fluorescence intensity than a
boundary line set to include 3% of the cells in the control sample were defined as
positive.
Depending on which fluorochrome the nanoparticles were labeled with, different
lasers and detectors were utilized. Nile red was excited with a green laser of
wavelength 561 nm and detected through a 582 nm filter with a 15 nm band
pass, and a 620 nm filter with a 30 nm band pass. Fluorescein acrylate and
fluoresceinamine was excited with a blue laser of wavelength 488 nm and detected
through a 525 nm filter with a 40 nm band pass.
Two different measures of positive cells were estimated from the samples:
1. The percentage of positive cells in the sample defined by the boundary line.
2. The relative amount of positive cells estimated by normalizing the MFI from
the samples to the MFI from untreated cells (corresponding to the autoflu-
orescence).
The Kaluza software from Beckman Coulter was used for data analysis, and to
acquire overlays of histograms.
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3.4 Investigation of intracellular nanoparticle distribution
with CLSM
The intracellular distribution of nanoparticles was studied with CLSM. For these
experiments, PC3 cells were grown in µ-slide 8-well plates (Ibidi, Thistle Scien-
tific). In each well, 15.000 cells/300 µl medium were seeded 48 hours before the
experiment, or 30.000 cells/300 µl medium 24 hours in advance. On the day of the
experiment, the growth medium was removed, and 300 µl of nanoparticle-medium
solution (20 µg/ml) was added. Incubation was done at 37◦C and 5% CO2 for the
desired period of time, usually approximately 1 hour.
Observation of the samples was done in a TCS SP8 from Leica. Excitation of
both nile red and fluorescein dyes was done with an argon laser with wavelength
of 488 nm. The water objective used had a magnification of 63X and a numerical
aperture of 1.2, and the confocal pinhole size was set to 1 airy unit. Images were
taken with a frame size of 1024×1024 pixels and a scan speed of 400 Hz. To achieve
maximum signal with minimal saturation and background disturbance the laser
intensity and gain was adjusted to an optimal level.
To investigate whether the spectral characteristics of nile red could be exploited
to distinguish between free and particle associated nile red in cells, λ-series were
recorded. The sample was illuminated with the 488 nm laser, and nile red emis-
sion was detected in 11 wavelength intervals between 520 and 700 nm. Following,
different regions of interest in the cells were defined, namely apparent vesicles and
cytosolic regions. The intensity values from each such region were collected at
every wavelength interval. These data were subsequently used to obtain the nile
red emission spectra from vesicles and cytosolic regions of the cells after nanopar-
ticle incubation. In addition, a tunable white laser was used to vary the excitation
wavelength in order to measure the excitation maximum in similar regions of in-
terest.
3.5 Quantification of nile red amount by
spectrophotometry
3.5.1 Total nile red content in the particles
The total nile red content in the nanoparticles was measured to determine how it
correlated with the theoretical value. By dissolving the poly(alkyl cyanoacrylate)
particles in tetrahydrofuran (THF), all encapsulated nile red should in theory be
released to the solution. 50 µl nanoparticle solution was added to 2 ml THF, before
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the mixture was stirred on a roller. Samples were measured in a spectrophotometer
both after 4 and 24 hours, to make sure all nanoparticles were properly dissolved.
In addition, a nanoparticle without encapsulated nile red was added to THF, in
order to rule out possible contribution from polymeric residues.
3.5.2 Nile red release from nanoparticles in cell medium
Experiments were performed to determine whether nile red was released from the
nanoparticles and into cell medium. A nanoparticle-medium solution with the
same concentration used for cell incubation (20 µg/ml) was added to 25 cm2 plas-
tic flasks and incubated at 37◦C and 5% CO2 for 3 hours. After incubation, the
samples were centrifuged at 21.000 rpm (approximately 50.000g) for 1.5 hours in
a Beckman Coulter Avanti J-30I. The centrifugation speed and time were chosen
since it has previously been used to sediment similar PBCA nanoparticles. [127]
Following centrifugation, sedimented nanoparticles were visible in the bottom of
the centrifuge tubes. If free nile red was present in the original nanoparticle so-
lution, or if parts of the fluorescent dye were released from the particles, nile red
would now be found in the supernatant. The supernatants from all centrifuged
solutions were collected and stored frozen until further use.
The nile red probe is efficiently quenched in aqueous solution, and therefore nile
red in the supernatant cannot be measured directly in a spectrophotometer. To
extract nile red from the cell medium, 1 ml of hexadecane was added to 3 ml of the
collected supernatants. Pure cell medium was also added to hexadecane, in order
to rule out possible contribution from components of the medium. These mixtures
were let to stay overnight on a roller. Next morning, the hexadecane phases were
collected for measurements.
3.5.3 Spectrophotometric measurements of nile red in the samples
A standard curve of nile red concentration versus fluorescence intensity was ob-
tained to quantify the amount of nile red in the samples. The standard curve was
generated by measuring the fluorescence intensity of solutions with known nile red
concentrations, ranging from 1 to 100 ng/ml. Since two different solvents were
used (hexadecane and THF), standard curves of nile red dissolved in each of these
had to be measured. Following, the data set was fitted to a linear model in Excel
(Microsoft Office). The line was set to begin at the origin, as zero concentration of
nile red was assumed to give no fluorescence. (Any solvent contribution is excluded
by using hexadecane/nile red as blank samples.)
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Measurements of the samples were done in a spectrophotometer (Gemini XPS
Fluorescence Microplate Reader, Molecular Devices). 200 µl solution was trans-
ferred into a white 96-well plate, before the fluorescence intensity was recorded.
2-3 parallels were measured from each concentration, and pure hexadecane/THF
was used as a blank sample to correct for contributions from the solvent. For
nile red dissolved in hexadecane, an excitation wavelength of 493 nm and emis-
sion wavelength of 540 nm was used. These wavelengths were chosen since they
corresponded approximately to the highest point on the absorbance and emission
spectra of nile red dissolved in hexadecane. From measurements of absorbance
and emission spectra of nile red dissolved in THF, an excitation and emission
wavelength of 527 nm and 603 nm were chosen.
The same protocol as described above was used for measuring the fluorescence in-
tensity of samples collected from the dissolved nanoparticles and the supernatants.
3.6 Toxicity studies
The cytotoxicity of poly(alkyl cyanoacrylate) nanoparticles was measured using
alamarBlue R© cell viability assay from Invitrogen. (See section 2.2.1) 24 hours
prior to the experiment, 20.000 cells/200 µl medium were seeded in each well of a
black 96 well plate (Corning R©), with flat and clear bottom.
On the day of the experiment, the growth medium from all wells was discarded.
The cells were then incubated with nanoparticle-medium solutions with 10 differ-
ent concentrations, increasing from 5 to 240 µg/ml, at 37◦C and 5% CO2 for 3
hours. The purpose was to examine how the cytotoxicity was affected by nanopar-
ticle concentration, and also if it varied with different PEGylation and monomer
composition. 4 replicas were used for each sample, including the control samples
with no added nanoparticles. After incubation, the cells were rinsed 3 times with
200 µl cell medium per well, before each well was added 110 µl of alamarBlue R©
reagent diluted 10 times in medium. Subsequently, the well plates were put back
into the incubator (37◦C, 5% CO2). An incubation time of 3 hours was chosen since
previous toxicity studies of similar poly(alkyl cyanoacrylate) nanoparticles added
to PC3 cells showed that the fluorescence intensity of alamarBlue R© increased lin-
early with incubation time between 2 to 4 hours. [126] Blank samples containing
only cell medium and alamarBlue R© reagent were also prepared in order to correct
for background fluorescence from the medium. To eliminate possible fluorescence
contribution from phenol red, the cell medium used in the toxicity experiments
did not contain this pH indicator.
The fluorescence intensity of alamarBlue R© was recorded using a microplate reader
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(Tecan Group Ltd.), with measurements done from the bottom with excitation
and emission wavelengths of 550±9 nm and 590±20 nm respectively. Since the
amount of fluorescence is proportional to the number of living cells, an estimation
of the percentage of viable cells can be done with the equation below:
Cell viability (%) =
(FINP − FIB)
(FIC − FIB) × 100, (9)
where FINP , FIC and FIB are the fluorescence intensity from samples with added
nanoparticles, untreated controls and blank samples respectively. These data were
then used to plot cell viability against nanoparticle concentration on a logarithmic
axis. The resulting dose response curve was fitted using Sigmaplot to a 4-parameter
logistic curve given by:
y = ymin +
(ymax − ymin)
[1 + ( x
EC50
)−Hill slope]
, (10)
where EC50 denotes the half maximal effective concentration, the Hill slope char-
acterizes the slope of the curve at its midpoint, and ymax and ymin are the top
and bottom of the curve respectively. ymax was constrained to be smaller than
or equal to 100% and ymin larger than or equal to 0%. The goodness of the fit
was determined by the coefficient of determination (R2) and the p-value of each
coefficient. P-values smaller than 0.05 were considered to indicate that the curve
was a good approximation to the data points.
From the dose response curves, two measures of nanoparticle cytotoxicity were
obtained:
1. The median lethal dose (LD50) is defined as the concentration required to
kill half of a tested population after a specified test duration. This value
was determined by reading out at which concentration the 50% cell viability
point intercepts with the graph.
2. The EC50 parameter defines the nanoparticle concentration that provokes a
response midway between the baseline (ymin) and maximum (ymax) response.
This value can be compared between experimental data independent on how
your data are normalized, i.e. even if the baseline and maximum level of cell
viability differs a lot between the tested nanoparticles.
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4 Results
4.1 Estimates of PEG chain densities
An estimate of the average PEG chain density on the surface of nanoparticles
coated with linear PEGs was performed by the procedure outlined in section 3.1.4.
In table 4.1, the resulting estimates of PEG density (ρPEG), average area occupied
by one PEG chain (APEG) and average distance between neighboring PEG chains
(D) are presented.
Table 4.1: Estimated PEG surface densities (ρPEG) on the different nanoparticle batches,
including approximate values for the surface area covered by one PEG chain (APEG)
and the average distance between neighboring chains (D). The estimates are based on
data obtained in NMR measurements.
PEG Batch ρPEG (nm
-2) APEG (nm
2) D (nm)
Jeffamine 1000
44 0.03 36.0 6.8
66 0.03 39.9 7.1
69 0.04 25.5 5.7
73 0.02 43.4 7.4
82 0.03 31.0 6.3
83 0.04 25.0 5.6
89* 0.06 15.7 4.5
Amino-PEG 750 75 0.03 37.7 6.9
Amino-PEG 2000 76 0.01 114.4 12.1
Amino-PEG 5000 77 0.003 401.5 22.6
OH-PEG-NH2 3400 74 0.02 57.3 8.5
*Particle produced from POCA.
All particle batches PEGylated with Jeffamine 1000 have comparable PEG density
values, except the POCA particle which has a twice as high PEG density on the
surface. Various amounts of PEG per gram oil phase are used during synthesis of
the different particles, giving no indication that the amount of PEG added influence
the PEG density. The results suggest that a change in particle composition from
PBCA to POCA can be of significance for the achievable PEG density.
The Amino-PEGylated nanoparticles have an evident decrease in PEG density
with increasing PEG chain length, meaning the average distance between neigh-
boring PEG chains are significantly larger for the long PEG chain than for the
short. The same number of PEG chains, i.e. equal amounts of mole PEG was
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added during synthesis of the particles, suggesting that longer PEG chains result
in lower surface density. Particle batch 74, coated with OH-PEG-NH2, has a twice
as high surface density as the particle coated with a PEG chain of similar length
(batch 76), possibly because both the hydroxyl and the amino group can react
with the monomer.
4.1.1 Expected PEG surface conformation
All particle batches were expected to have their PEG chains in a mushroom con-
formation. (See table 4.2) In other words, the relative polymer size, or Flory radius
(RF ), of all PEG chains were smaller than the average distance between two neigh-
boring PEGs on the surface. This implies that all utilized particles have relatively
low PEG surface density, independent of the number of PEG chains attached to
the surface and the PEG chain molecular weight.
Table 4.2: The Flory radius (RF ) of the different PEG chains, and the expected PEG
surface conformations on all nanoparticle batches.
PEG RF (nm) Batch PEG conformation
Jeffamine 1000 2.1
44 Mushroom
66 Mushroom
69 Mushroom
73 Mushroom
82 Mushroom
83 Mushroom
89* Mushroom
Amino-PEG 750 1.9 75 Mushroom
Amino-PEG 2000 3.4 76 Mushroom
Amino-PEG 5000 6.0 77 Mushroom
OH-PEG-NH2 3400 4.7 74 Mushroom
*Particle produced from POCA.
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4.1.2 Correlation between PEG chain density and ζ-potential
The correlation between PEG density and ζ-potential for the particles are not
as expected. Rather counterintuitive, the plot in figure 4.1 shows that particles
with the most positive ζ-potentials have PEG densities in the lower range of the
estimated values. This relation holds even if the fluorescein labeled particles are
disregarded, in case association with fluorescein alters the surface properties in
comparison with nile red loaded particles. The result suggests that an increase in
ζ-potential cannot directly be taken as an indication on higher PEG density on
the surface, exemplified by how the particle with the highest PEG density (the
POCA particle), also has one of the most negative ζ-potentials measured.
Figure 4.1: Correlation between measured ζ-potential and estimated density of PEG
chains on the particle surface. The data points are labeled according to the fluorescent
label of the nanoparticles: nile red (blue) and fluorescein (red). The y-axis represents
PEG density expressed as number of PEG chains per nm2, and the x-axis displays the
ζ-potential in mV.
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4.2 Cellular uptake of fluorescein-labeled nanoparticles
Experiments performed in the project thesis showed that nile red could be dis-
sociated from the nanoparticles. New batches labeled with fluorescein dyes were
therefore prepared to determine whether the fluorescent marker remained associ-
ated with the particles after washing of the samples and if the cellular uptake was
energy dependent or not.
4.2.1 Cellular uptake of fluorescein acrylate nanoparticles
After experiments performed with fluorescein acrylate nanoparticles it was found
that the labeling protocol was not satisfactory. Figure 4.2 shows overlay histograms
from FCM analyses of cells incubated with particles with encapsulated fluorescein
acrylate. The results after testing with particle 68 indicate that fluorescein acry-
late can dissociate from the nanoparticles, since the fluorescence intensity from
the samples does not differ between cells incubated at 4◦C and 37◦C (Figure 4.2a),
suggesting energy independent uptake based on diffusion of the fluorescent marker
into cells rather than endocytosis of the particles. It is also probable that small
amounts of fluorescein acrylate remained associated with the particles after synthe-
sis, since the MFI only was about 3 times higher than that of the control samples,
corresponding to a very slight increase. After incubation with particle 69 (Fig-
ure 4.2b) it is not possible to discriminate between cells incubated with particles
and untreated cells, giving no indication on either endocytosis of nanoparticles
or diffusion of fluorescein acrylate into cells. This result can be explained with
a high degree of fluorescein acrylate leakage during dialysis, meaning very little
fluorescein acrylate remained in the core of the particle after synthesis.
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(a) Batch 68 (b) Batch 69
Figure 4.2: Overlay histograms obtained in FCM analyses of PC3 cells incubated with
fluorescein acrylate labeled nanoparticles for 3 hours at 37◦C and 4◦C respectively. The
fluorescence intensity is shown both after 3 times rinsing with PBS, and after additional
3 times centrifugation.
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4.2.2 Cellular uptake of fluoresceinamine nanoparticles
None of the procedures for labeling nanoparticles with fluoresceinamine was found
to be optimal. Figure 4.3 shows overlay histograms from FCM analyses of cells
incubated with particles that had fluoresceinamine coupled to the surface. The
first testing of particle batch 66 gave promising results since the cellular uptake
seemed to be energy dependent. (Histogram shown in appendix figure B.1) Still,
the MFI of cells incubated with nanoparticles was only about twice as high as
the untreated cells, meaning very little fluoresceinamine was associated with the
particle after synthesis. Therefore, the particle batch was modified by adding 10
times more fluoresceinamine, with the resulting overlay histogram presented in
figure 4.3a. From the histogram, this particle looks like an ideal candidate for fur-
ther studies. The cellular uptake is clearly energy dependent and does not diminish
with more extensive washing of the samples. Unfortunately, after attaching more
fluoresceinamine to the surface, the particles became very unstable and suffered
from severe problems with aggregation. This was observed in the CLSM, when
cells appeared all black, but big, bright spots of fluorescence could be observed on
the cell membrane and in the surrounding medium after particle incubation. (Fig-
ure B.2 in appendix.) Aggregation of the particles was also confirmed by dynamic
light scattering measurements; after modification the size increased from 150 nm
to 2.8 µm.
After experiments performed with batch 82 and 83, both particles were found
to have non-detectable amounts of fluoresceinamine coupled to the surface, i.e.
similar results were obtained as with the fluorescein acrylate labeled particle batch
69. It was not possible to distinguish between untreated cells and cells incubated
with nanoparticles (see figure 4.3b and 4.3c), indicating neither endocytosis of
nanoparticles nor diffusion of fluoresceinamine into cells. This can be explained
with observations done during synthesis: The amine group on fluoresceinamine
was supposed to be coupled directly onto the surface of the particle by initiating
the polymerization, but instead the reaction was too rapid and destabilized the
miniemulsion, leading to separate, solid lumps of fluoresceinamine and little or
nothing remaining on the particle surface.
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(a) Batch 66 (b) Batch 82
(c) Batch 83
Figure 4.3: Overlay histograms obtained in FCM analyses of PC3 cells incubated with
the fluoresceinamine labeled nanoparticles for 3 hours at 37◦C and 4◦C. Batch 66 is
modified from the original by attaching 10 times more fluoresceinamine to the particle
surface. The fluorescence intensity is shown both after 3 times rinsing with PBS, and
after additional 3 times centrifugation.
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4.3 Effects of washing on nile red positive cells
Washing reduces the amount of nile red fluorescence from the samples. This phe-
nomenon was first discovered in the project thesis, and further confirmed by ex-
periments done in this work. Figure 4.4 demonstrates how the MFI of cells after
incubation with various nanoparticles for 3 hours is influenced by the different
steps of washing, and with a representative histogram presented in figure 4.5. The
trend of decreasing fluorescence intensity with more extensive washing is valid for
all the nile red labeled nanoparticle batches tested.
Figure 4.4: PC3 cells positive for nile red after 3 hours incubation with all nile red
labeled nanoparticles. The MFI normalized to the MFI of untreated cells is plotted as
a function of the different steps of washing: 3 times rinsing with PBS, 1, 2 and 3 times
spin down.
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Figure 4.5: Overlay histogram obtained in FCM analysis of PC3 cells incubated with
nanoparticle batch 73 for 3 hours at 37◦C. The fluorescence intensity is shown after all
steps of washing: 3 times rinsing with PBS, 1, 2 and 3 spin downs, and is representative
for the trend observed with all other nile red labeled nanoparticle batches.
4.4 Cellular uptake of nile red loaded nanoparticles
To investigate whether the cellular uptake of nanoparticles with encapsulated nile
red was dependent on different particle properties, some candidates were chosen
for further comparison. The particle batches 71B, 72 and 74 were eliminated
because they were found to be relatively unstable and had much bigger sizes (from
approximately 400 to 800 nm) than what was desired. Batch 82 and 83 were
also left out since they were labeled with fluoresceinamine in addition to nile
red, something which could affect the surface properties of the particles. The
remaining particle batches (44, 73, 75, 76, 77, 79 and 89) were classified according
to their PEGylation: Jeffamine or Amino-PEG. Only these 7 particles are further
investigated in the thesis, and to make it easier for the reader, the particle batches
will from now on be referred to according to their properties. They are given
names on the form: B/O-JF/AMXXXX; the first letter representing monomer
composition (B for butyl and O for octyl), the PEG chain type after the hyphen
(JF for Jeffamine and AM for Amino-PEG), and at last the PEG chain length as
molecular weight. Particle batch 44 (B-JF1000-Hex) is distinguished from 73 by
(B-JF1000) by adding ”Hex” to the name to account for the use of hexadecane
and not Miglyol as co-stabilizer.
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In all FCM experiments, nile red fluorescence was detected in two channels. Both
channels showed similar fluorescence patterns, but since the intensity was strongest
in the 620 nm filter, only data from this spectral interval are presented in the fol-
lowing sections. A comparison of the fluorescence intensity from the two channels
are given in appendix C.
4.4.1 Cellular uptake of Jeffamine PEGylated nanoparticles
Nile red is transferred to a high degree into PC3 cells from Jeffamine PEGylated
nanoparticles. In figure 4.6, a comparison of the cellular uptake after 3 hours
incubation with the Jeffamine PEGylated particles is presented, and overlay his-
tograms are given in figure 4.7. The particles differ a bit in how much nile red they
are able to deliver to cells (demonstrated by differences in normalized MFI after 3
times rinsing with PBS), although here it is important to note that B-JF1000-Hex
has 5 times less nile red encapsulated, such that the fluorescence intensity values
resulting from this particle are not directly comparable to the others. An increase
in PEG chain length from 1000 to 2000 Da (compare B-JF1000 and B-JF2000)
gave no difference in cellular uptake, whereas the POCA particles (O-JF1000)
seem to have a slightly lower ability to deliver nile red to cells than its PBCA
counterpart (B-JF1000).
The process of nile red transfer is mainly energy independent, since incubation with
nanoparticles give comparable cellular uptake at 37◦C and 4◦C. Slightly more nile
red is transferred to cells at 37◦C, but after washing the amount of nile red fluo-
rescence is reduced to values close to that of the control samples, indicating no or
very little energy dependent uptake. The nile red fluorescence intensity is reduced
by similar amounts from cells incubated at both temperatures. This is observed
in the overlay histograms (figure 4.7), where the histogram peaks, although ini-
tially located at different intensity values, are shifted by similar amounts to lower
intensity with washing.
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(a) Nile red MFI after Jeffamine nanoparticle incubation
(b) Nile red positive cells after Jeffamine nanoparticle incubation
Figure 4.6: PC3 cells positive for nile red after 3 hours incubation at 37◦C (red bars)
and 4◦C (blue bars) with Jeffamine PEGylated nanoparticles. The MFI normalized to
the MFI of control samples is presented in (a) and the percentage of positive cells in (b).
All data are shown both after 3 times rinsing with PBS (left side of the chart), and after
additional 3 times centrifugation (right side of the chart).
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(a) B-JF1000-Hex (b) B-JF1000
(c) B-JF2000 (d) O-JF1000
Figure 4.7: Overlay histograms obtained in FCM analysis of PC3 cells incubated with
Jeffamine PEGylated nanoparticles for 3 hours at 37◦C and 4◦C. The fluorescence
intensity is shown both after 3 times rinsing with PBS, and after additional 3 times
centrifugation.
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4.4.2 Cellular uptake of Amino-PEGylated nanoparticles
Amino-PEGylated nanoparticles are able to deliver high amounts of nile red to
PC3 cells, just like the Jeffamine PEGylated. Figure 4.8 shows a comparison of
cellular uptake after 3 hours incubation with the Amino-PEGylated nanoparticles,
and overlay histograms are given in figure 4.9. A decrease in cellular uptake with
increasing PEG chain length is observed (decreasing normalized MFI from B-
AM750 to B-AM5000 after 3 times rinsing with PBS, figure 4.8a) After additional
3 times centrifugation, this trend is no longer visible, since all MFI values are
diminished down to a level comparable to that of the control samples.
The transfer of nile red into cells is relatively independent of temperature. More
nile red is delivered to cells at 37◦C, but after washing the fluorescence intensity
is considerably reduced, indicating no or little energy dependent uptake. The dif-
ference in cellular uptake at 37◦C and 4◦C is more prominent when examining
the percentage of positive cells (figure 4.8b), although it is not the case for cells
incubated with B-AM5000. Washing reduces the nile red fluorescence intensity
by similar amounts from cells incubated at both temperatures. This is observed
in the overlay histograms (Figure 4.9), where the histogram peaks, although ini-
tially located at different intensity values, are shifted by similar amounts to lower
intensity with washing.
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(a) Nile red MFI after Amino-PEG nanoparticle incubation
(b) Nile red positive cells after Amino-PEG nanoparticle incubation
Figure 4.8: PC3 cells positive for nile red after 3 hours incubation at 37◦C (red bars)
and 4◦C (blue bars) with Amino-PEGylated nanoparticles. The MFI normalized to the
MFI of control samples is presented in (a) and the percentage of positive cells in (b).
All data are shown both after 3 times rinsing with PBS (left side of the chart), and after
additional 3 times centrifugation (right side of the chart).
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(a) B-AM750 (b) B-AM2000
(c) B-AM5000
Figure 4.9: Overlay histograms obtained in FCM analysis of PC3 cells incubated with
Amino-PEGylated nanoparticles for 3 hours at 37◦C and 4◦C. The fluorescence intensity
is shown both after 3 times rinsing with PBS, and after additional 3 times centrifugation.
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4.5 Intracellular distribution of nile red after nanoparticle
incubation
To complement the uptake studies, CLSM images were taken to examine the in-
tracellular distribution of nile red after nanoparticle incubation. One image, taken
after incubation with B-JF1000-Hex, is shown in figure 4.10. From this image,
there is no doubt that the fluorescence is intracellular in origin, and no evidence of
surface bound particles was found in any of the experiments. Nile red fluorescence
was seen both as a diffuse staining of the entire cell cytoplasm and as localized,
brighter spots. Not all cells showed as distinct and high-intensity spots as the two
cells showed in this figure, and the number of spots also varied between cells within
one sample. The presence of localized spots can indicate nanoparticles in vesicles
after endocytosis, but it can also be free nile red staining lipid compartments in
the cells. Further CLSM studies were therefore performed to see if the spectral
characteristics of nile red could be used to distinguish between free and particle
associated nile red.
Figure 4.10: CLSM image of PC3 cells incubated with B-JF1000-Hex. Nile red fluores-
cence is depicted in red. The scale bar is 15 µm.
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4.5.1 Spectral analysis of nile red
λ-series were recorded in the CLSM to determine whether the nile red emission
spectrum varied between areas in the cytosol and what appeared as vesicles in the
imaged cells. The spectral analysis of cells incubated with nanoparticles suggested
that nile red in localized spots is bound to more hydrophobic compounds than
in the diffuse staining of the cytosol. Figure 4.11b shows a representative CLSM
image after incubation with B-JF1000-Hex for approximately 1 hour, where ex-
amples of both a cytosolic and vesicular region of interest are given. The resulting
emission spectra obtained from these regions are displayed in figure 4.11a, where
a nanoparticle spectrum measured in a spectrophotometer is added for compara-
tive purposes as well. The measured emission maximum of the vesicle and cytosol
spectrum is at 584 and 616 nm respectively. This indicates that nile red in vesicles
is bound to more hydrophobic compounds than in the cytosol. The nanoparticle
spectrum has an emission maximum at approximately 595 nm, closer to the vesicle
peak than the cytosolic peak.
A similar study was done after 1 hour incubation with particle B-JF1000, with
results presented in figure 4.12. The measured emission maxima were the same
as for particle B-JF1000-Hex, but the spectrum from the vesicle region is wider
and with a less defined peak. When the sample was examined in the CLSM, the
vesicles appeared less visible than in images of cells incubated with B-JF1000-
Hex, which made it more difficult to define accurate vesicular regions of interest.
This may have caused the broadening of the spectrum towards higher wavelengths,
since areas in the cytosol may have contributed in the collected intensity values.
In general, the process of defining vesicular regions of interest was complicated
by vesicle movement during recording of the λ-series. Despite this, the results
confirmed that nile red in localized spots is associated with more hydrophobic
compounds than in the cytosol.
Another finding confirmed nile red association with different compounds in vesicles
and cytosol. Recorded excitation/emission scans in the CLSM gave maximum
intensity at approximately 525/585 nm and 555/625 nm for vesicular and cytosolic
areas in the cells respectively. These results correspond with those previously
presented in that the emission maximum from the cytosol spectrum is shifted
towards higher wavelengths when compared to the vesicle spectrum.
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(a)
(b)
Figure 4.11: Different nile red emission spectra after excitation with a 488 nm laser
are displayed in figure (a). The nanoparticle spectrum (dotted line) is measured in a
spectrophotometer, whereas the spectra from cytosolic and vesicle associated nile red
are obtained by recording λ-series in the CLSM. The plotted fluorescence intensity val-
ues are averages from 23 vesicular and 12 cytosolic regions from several cells with the
corresponding standard deviations plotted as error bars. An illustration of a vesicular
(circle) and cytosolic region (square) is given in (b), where a representative CLSM image
is shown after approximately 1 hour incubation with nanoparticle B-JF1000-Hex. Nile
red fluorescence is depicted in red, and the scale bar is 10 µm.
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(a)
(b)
Figure 4.12: Different nile red emission spectra after excitation with a 488 nm laser
are displayed in figure (a). The nanoparticle spectrum (dotted line) is measured in a
spectrophotometer, whereas the spectra from cytosolic and vesicle associated nile red
are obtained by recording λ-series in the CLSM. The plotted fluorescence intensity val-
ues are averages from 14 vesicular and 14 cytosolic regions from several cells with the
corresponding standard deviations plotted as error bars. An illustration of a vesicular
(circle) and cytosolic region (square) is given in (b), where a representative CLSM image
is shown after approximately 1 hour incubation with nanoparticle B-JF1000. Nile red
fluorescence is depicted in red, and the scale bar is 10 µm.
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4.6 Spectrophotometric measurements of nile red
Spectrophotometric measurements on samples from the 7 particle batches chosen
for further studies gave an estimate of the total nile red content in the particles,
and the amount of nile red released to cell medium from nanoparticles after 3
hours. The values are presented in table 4.3, and the standard curves used for
determining the amount of nile red in the samples are given in appendix D.
Table 4.3: An overview of the theoretical and measured nile red content in 20 µg/ml
nanoparticles, as well as the amount of nile red released from this concentration of
nanoparticles into cell medium after 3 hours. The relative release in percent (ratio of
released amount to the total content in the particles) is also presented.
Batch Theoretical
content
(ng/ml)
Measured
content
(ng/ml)
Released to
cell medium
(ng/ml)
Relative
release (%)
B-JF1000-Hex 4 6.2 2.8 44.3
B-JF1000 20 25.1 13.7 54.5
B-JF2000 20 25.1 11.7 46.4
O-JF1000 20 20.3 14.2 69.6
B-AM750 20 33.2 14.6 44.0
B-AM2000 20 36.0 17.2 47.7
B-AM5000 20 20.4 9.5 46.5
4.6.1 Total nile red content in the nanoparticles
The measured total nile red content in the particles varies between batches, but
all values are comparable or higher than the theoretical values. This shows that
even if equal amounts of nile red were added during synthesis, the actual amount
encapsulated can still differ. Measurements were done both 4 and 24 hours after
the particles were added to THF (data only shown for 24 hours), with no or only
a slight increase in detected amount of nile red, suggesting the particles were
completely dissolved in THF after 24 hours. Altogether, it is plausible to believe
that the resulting values give a reasonable measure on the total content in the
particles, and at least it seems like the estimate is not too low.
Results 65
4.6.2 Nile red release from the nanoparticles
A rather high amount of nile red was released from the nanoparticles to cell medium
after 3 hours. The amount of released nile red varied from batch to batch, but
when related to the actual amount present in the particles, the relative release (the
ratio of released amount to the total content in the particles) is fairly equal between
the majority of the batches. Altogether, the results suggest that the nanoparticles
loose around 45% of their associated nile red marker after 3 hours in cell medium,
except B-JF1000 and O-JF1000 which loose even more, approximately 55% and
70% respectively.
4.7 Toxicity of poly(alkyl cyanoacrylate) nanoparticles
The cytotoxic effect of the 7 nanoparticle batches chosen for further testing was
investigated by the alamarBlue R© cell viability assay. Table 4.4 gives a comparison
of the EC50 and LD50 values estimated after 3 hours of nanoparticle exposure. The
cell viability data after toxicity studies of the POCA particle (O-JF1000) do not
form a bottom plateau (which would define ymin), and fitting of a dose response
curve was not possible. Hence, the EC50 value from this particle is omitted in the
table.
Table 4.4: A summary of the obtained EC50 and LD50 values after testing the toxicity
of different nanoparticle batches in PC3 cells.
PEG Batch EC50 (µg/ml) LD50 (µg/ml)
Jeffamine
B-JF1000-Hex 26.8 29.1
B-JF1000 34.1 34.2
B-JF2000 32.3 32.9
O-JF1000 >240
Amino-PEG
B-AM750 27.2 29.2
B-AM2000 30.5 32.0
B-AM5000 53.7 57.2
4.7.1 Toxicity of Jeffamine PEGylated nanoparticles
The POCA based nanoparticle O-JF1000 is significantly less cytotoxic than its
PBCA counterparts (B-JF1000-Hex, B-JF1000, B-JF2000). Within 3 hours of
nanoparticle exposure, the cell viability after incubation with O-JF1000 does not
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decrease lower than approximately 70% in the range of concentrations tested,
whereas around 10% of cell survival is seen with the 3 other particles in the
same interval. This is shown in figure 4.13 where the dose response curves after
alamarBlue R© measurements of Jeffamine PEGylated nanoparticles are presented.
The reduced cytotoxicity of O-JF1000 is ascertained to stem from the change in
monomer composition, since all other physicochemical characteristics are compa-
rable to particle B-JF1000. (See table 3.1 for a comparison.)
After 3 hours exposure, PC3 cells can tolerate at least 8 times higher concentration
of POCA nanoparticles than PBCA particles. This is evident since the LD50 value
of O-JF1000 is assumed to be larger than 240 µg/ml, whereas the corresponding
PBCA particles have LD50 values ∼30 µg/ml. The fitted curves from testing with
particle B-JF1000-Hex, B-JF1000 and B-JF2000 have R2 values larger than 0.9812
and p-values for all coefficients smaller than 0.0095, indicating that the curves, and
hence also the LD50 values, are a good approximation to the data.
The Jeffamine PEGylated PBCA particles showed comparable cytotoxicity in PC3
cells; all had a steep decrease in cell viability around 20 µg/ml and only small
variations in the LD50 and EC50 values between them. An increase in PEG chain
length from molecular weight of 1000 to 2000 Da, between batch B-JF1000 and
B-JF2000, does not seem to influence the toxicity. When comparing B-JF1000-
Hex and B-JF1000, it is not possible to determine whether the kind of co-stabilizer
used (hexadecane vs. miglyol) and cross-linking of the PBCA polymer in the parti-
cle affect the cytotoxicity. A large variation between experiments was experienced
when B-JF1000-Hex was tested. Because of this, even though B-JF1000-Hex come
up as slightly more toxic from the EC50 and LD50 values, the difference is small
compared to the standard deviations in this concentration interval, and no con-
clusion regarding the effect of co-stabilizer and polymer cross-linking on particle
cytotoxicity can be given.
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Figure 4.13: Cytotoxicity of Jeffamine PEGylated nanoparticles after 3 hours exposure,
measured by the alamarBlue R© assay. The obtained data are averages of 2 independent
experiments, with the corresponding standard deviations plotted as error bars. The y-
axis represents cell viability expressed as a % of control samples without added nanopar-
ticles, and the x-axis displays increasing nanoparticle concentrations on a logarithmic
scale. The solid drawn lines are fitted dose response curves, while the markers represent
the averaged data points from the alamarBlue R© measurements. All fitted curves have
R2 values larger than 0.9812 and p-values for all coefficients smaller than 0.0095.
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4.7.2 Toxicity of Amino-PEGylated nanoparticles
An Amino-PEG chain length of 5000 Da reduces the cytotoxicity in PC3 cells com-
pared to particles with shorter PEG chains. As can be seen from the dose response
curves in figure 4.14, after 3 hours exposure, the particle with the longest PEG
chain, B-AM5000, is the least cytotoxic of the Amino-PEGylated nanoparticles.
The reduced cytotoxicity of B-AM5000 is ascertained to stem from the increase in
PEG chain length, since all other physicochemical characteristics are comparable
to particles B-AM750 and B-AM2000. (See table 3.1)
The LD50 and EC50 values suggest that PC3 cells can tolerate approximately
1.8 times higher concentration of B-AM5000 than of particles with shorter PEG
chains. All fitted curves have R2 values larger than 0.9875 and p-values for all
coefficients smaller than 0.0276, indicating that the curves, and hence also the
LD50 and EC50 values, are a good approximation to the data.
The toxicity of B-AM750 and B-AM2000 in PC3 cells was comparable, with only a
slight difference in LD50 and EC50 values, indicating that an increase in PEG chain
length from molecular weight of 750 to 2000 Da does not influence the cytotoxic-
ity. This corresponds with results for Jeffamine PEGylated particles presented in
the previous section, where no difference in toxicity between particles with chain
lengths increasing from 1000 to 2000 Da was observed. Since B-AM5000 with a
PEG chain length of 5000 Da was less cytotoxic, the results altogether suggest that
a higher molecular weight than 2000 Da is needed to see a decrease in cytotoxicity
after 3 hours exposure to PBCA nanoparticles.
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Figure 4.14: Cytotoxicity of Amino-PEGylated nanoparticles after 3 hours exposure,
measured by the alamarBlue R© assay. The obtained data are averages of 2 independent
experiments, with the corresponding standard deviations plotted as error bars. The y-
axis represents cell viability expressed as a % of control samples without added nanopar-
ticles, and the x-axis displays increasing nanoparticle concentrations on a logarithmic
scale. The solid drawn lines are fitted dose response curves, while the markers represent
the averaged data points from the alamarBlue R© measurements. All fitted curves have
R2 values larger than 0.9875 and p-values for all coefficients smaller than 0.0276.
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5 Discussion
The goal of the current project has been to investigate what effect different PEGy-
lation and monomer composition of poly(alkyl cyanoacrylate) nanoparticles had
on cellular uptake, hydrophobic probe release and cell viability. In this section I
will discuss my main findings, before finally making some general considerations
about the significance of the results for further work with the nanoparticles.
5.1 PEG densities on the nanoparticles
All particles used have their PEG chains in a mushroom formation, independent
of PEG type, number of PEGs attached and the PEG chain molecular weight,
implying low PEG surface densities on all batches. The PEG densities of particles
coated with chains of equal length were shown not to depend on the amount of PEG
added during synthesis, indicating that addition of more PEG not will increase the
density further, and that a change in either PEG type or the protocol for preparing
the particles are necessary to achieve higher PEG density. Peracchia et al. have
e.g. reported that the pH of the polymerization medium influences the amount of
PEG attached to the surface of poly(isobutyl cyanoacrylate) nanoparticles. [128]
There is not an abundance of articles reporting on PEG chains per area on the
surface of polymeric nanoparticles to compare the estimated values with. Some
studies estimate PEG density from the amount of PEG added during synthesis
(e.g. in references [129, 130, 131]), which is clearly not a valid assumption for par-
ticles prepared by the miniemulsion process used in this project. There are still a
few examples where quantitative analysis of PEG chain density on polymeric par-
ticles has been performed. Wu et al. estimated a density of ∼1.5 chains per nm2
on PBCA nanoparticles prepared by the miniemulsion method with a TWEEN 80
PEG [132], which is approximately 5 times higher than what was achieved with
the Jeffamine 1000 PEGylated PBCA particles. This indicates that the choice of
a linear or branched PEG can influence the PEG surface density. Peracchia and
colleagues calculated a density of 0.7 chains/nm2 on the surface of poly(isobutyl
cyanoacrylate) nanoparticles, with a relatively long PEG (5000 Da) [133], corre-
sponding to a density at least a factor 100 larger than what was estimated for the
B-AM5000 batch. Other authors have also reported on significantly higher PEG
densities than what have been estimated here. The area occupied by one PEG
chain on the surface have been found to be: 15 nm2 for a PEG 5000 chain attached
to polylactide nanoparticles [134], 35 nm2 for a PEG 7500 chain on polystyrene
nanospheres [135] and 9.3 nm2 on relatively bigger latex spheres (6 µm) [136].
Higher PEG densities have also been demonstrated on different carriers, such as
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gold nanoparticles [137], altogether suggesting a relatively low PEG density on the
particles used in this project compared to what is possible.
An effective shielding of the particle surface with a PEG coat is of importance to
obtain sufficient circulation times in vivo. [15, 16, 45] Further studies to investigate
whether the PEG layer present on the particles reduce plasma protein adsorption,
and thereby complement activation and uptake by the MPS, need to be performed.
Before that, the theoretical model published by Jeon and co-workers [138, 139]
can give some indications to whether a higher surface coverage is necessary or not.
For PEG chains attached to a planar hydrophobic surface, the model predicts
that optimal protein repulsion occurs with long PEG chains and high surface
density. [138] It was also calculated that an average distance between neighboring
PEG chains of ∼1-1.5 nm is ideal for resisting adsorption of proteins ranging from
2-8 nm in size. [139] The estimated values for the distance between PEG chains
found in this work are at least 4 times higher than the values predicted from
the model, suggesting that a higher PEG surface density is necessary to achieve
optimal protein repulsion. The model has also been shown to be in agreement
with experimental results. [130, 140]
Influence of PEG chain length
A clear reduction in PEG density with chain length was found. This can be
explained by already attached PEG chains on the surface that induce a steric
repulsion of the PEG remaining in the solution, resulting in less PEG chains able
to come close enough to the particle surface to react with the monomer. The
repulsive force will increase in strength with PEG chain length, thereby explaining
the gradual decrease in PEG density seen between particles coated with Amino-
PEG 750, 2000 and 5000. Corroborating with my results, Wu and colleagues also
found that the PEG density on PBCA particles decreased when the length of the
PEG chain increased. [132]
Even if an evident decrease in PEG density is observed with longer PEG chains,
this does not directly imply that the surface coverage is poorer. A longer PEG
chain has a larger Flory radius, meaning it occupies more area on the surface
compared to a smaller PEG. In other words, fewer long PEG chains are needed to
cover the same surface area of a particle. This can be exemplified by comparing the
Amino-PEGylated particles: By relating the total area occupied by the PEG chains
(piR2F × NPEG) to the surface area of the particle, a relative surface coverage of
∼30% was obtained for all 3 particles, regardless of their difference in PEG density.
Altogether, this shows that comparing PEG densities is useful when particles are
PEGylated with chains of equal length, but if the chain lengths are different, also
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the polymer size must be taken into account in order to say something about the
surface coverage provided by the PEG chains.
A longer PEG chain will, even if present in the mushroom regime, extend further
out from the surface than a shorter PEG chain, creating a ”thicker” PEG layer,
as illustrated in figure 5.1. The effect of a thicker PEG layer should not be dis-
regarded, as it is believed to be a determining factor in how effective the PEG
coat is at reducing protein adsorption. [45, 138] (See section 2.1.4) If you compare
particles with their PEG chains present in the same conformation, this means that
a particle surface can be equally well or even better protected with a long PEG
chain present in lower density as with a shorter chain present in higher density.
Figure 5.1: An illustration showing two nanoparticles PEGylated with a long (left) and
short (right) PEG chain. The longest PEG chain extends further out from the surface
than the short, increasing the relative ”thickness” of the PEG layer, indicated with the
black circle.
Correlation between PEG density and ζ-potential
The ζ-potential is often used as an indicator on the degree of PEG covering the
surface of poly(alkyl cyanoacrylate) nanoparticles, by assuming that more nonionic
PEG chains attached to the surface will shield the negatively charged surface
groups better, resulting in a more positive ζ-potential. This seems like a reasonable
assumption, and it has indeed been demonstrated that addition of more PEG
during synthesis yield higher ζ-potentials. [133, 141, 142] From my results, this
expected correlation was not observed, suggesting that one has to be cautious
with using the ζ-potential to directly interpret PEG surface density.
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One possible explanation to the discrepancy is inconsistencies in the ζ-potential
measurements, as it has been observed in our lab that the measured values can vary
according to the concentration of nanoparticles in the sample. Other experimental
errors can also influence the result, since the estimated PEG densities do not
have very large variations between them. Moreover, the shielding of the negative
surface groups might not be as efficient as in theory, because of low coverage on the
particle surface, with PEG chains in the mushroom conformation. A surface layer,
containing residues from components used in the synthesis that are not removed
by dialysis, have been observed after particle preparation. Nile red, unpolymerized
monomer and possibly also PEG chains and surfactants, can associate with the
hydrophobic particle surface if they are redundant in the solution. That some PEG
is present in this surface layer, or elsewhere in the particle solution, is confirmed
by the NMR analyses, since less PEG was detected after centrifugation of the
particle samples. The presence of this surface layer might somehow contribute to
the counterintuitive correlation between ζ-potential and PEG density, if it shields
or otherwise interferes with the measured surface charge on the particles.
5.2 Cellular uptake of nanoparticles
No definite proof of nanoparticle internalization in PC3 cells has been found in
this study. Evaluation of nile red loaded nanoparticle uptake was complicated by
probe dissociation from the particles, which has also been reported previously in
the literature. [113, 114] The results suggest that detected nile red fluorescence
after nanoparticle incubation stems from free nile red staining intracellular com-
partments rather than particle associated nile red, based on observations regarding
reduction in fluorescence intensity after washing, temperature dependence of up-
take and spectral analysis of intracellular nile red. It is also supported by how
previous studies with pharmacological inhibition of endocytosis did not decrease
the amount of nile red positive cells. [17]
Effects of washing on nile red fluorescence intensity
After washing, the fluorescence intensity from all samples was considerably re-
duced, in most cases showing values comparable to the control samples. Previously
performed experiments confirmed the effect of washing on nile red positive cells
with CLSM imaging as well. [17] If cells had internalized nanoparticles, it is very
unlikely that particles in vesicles could be washed out of the cells during spin down,
especially when considering centrifugation of cell samples to be common practice.
Rather, the most probable explanation is eﬄux of nile red from cells, when nile
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red containing medium is replaced by nile red free medium during the washing
procedure, caused by a concentration gradient across the cell membrane. In line
with this, Xu. et al. were able to detect a decrease in intracellular nile red fluo-
rescence during CLSM imaging, when nanoparticle-medium solution was replaced
with particle free medium. [113] The reduction in nile red fluorescence with more
extensive washing indicates that detected nile red is free and not encapsulated in
particles.
Temperature dependence of cellular uptake
A slight temperature dependence on cellular uptake of nile was observed. All
nanoparticle batches tested were able to deliver more nile red to cells at 37◦C
compared to 4◦C. After washing, the MFI from cells incubated with nanoparticles
and untreated cells were comparable at 37◦C and 4◦C, whereas a more prominent
difference was observed in the percentage of positive cells for some of the particle
batches. At first glance, this might indicate energy dependent uptake, but it can
also be a consequence of more delivered free nile red at 37◦C. When cells have
taken up more nile red it follows that more extensive washing is required to eﬄux
the same amount of nile red from the cells. In light of the other results, the latter
explanation is more plausible.
Spectral analysis of intracellular nile red
Spectral analysis of intracellular nile red clearly showed that the fluorescent probe
is associated with different compounds in cytosol and in what appeared as local-
ized brighter spots. The emission maximum shifted towards higher wavelengths
in cytosol compared to the spots, indicating nile red bound to less hydrophobic
compounds in this area of the cells. [110, 111]
The fluorescence from vesicular regions was hypothesized to stem from nanopar-
ticles in endocytic vesicles or free nile red staining lipid compounds. From the
spectral analysis of intracellular nile red, the emission spectrum from the vesicu-
lar regions overlap with the nanoparticle emission spectrum, and therefore do not
exclude the possibility for detected nile red fluorescence in localized spots to be
nanoparticles in endocytic vesicles. Despite this, if the result from the spectral
analysis is seen in connection with the cellular uptake studies and the high esti-
mated nile red release from particles, it is more probable that the bright spots
observed in CLSM images are caused by free nile red that has diffused into cytosol
and subsequently stained lipid compartments. Free nile red will fluoresce intensely
in the presence of phospholipid vesicles [111], like endo- and lysosomes. Master
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student Sofie Snipstad demonstrated no co-localization of nile red with early endo-
somes [143], whereas Brown et al. have shown high nile red affinity for lysosomes
and other lipid droplets. [144], altogether suggesting a higher probability for free
nile red to stain lysosomes than early endosomes. Further studies (for instance
to investigate co-localization with lysosomes) must be performed in order to shed
more light on which intracellular compounds and membranes nile red has highest
affinity for.
Does endocytosis of poly(alkyl cyanoacrylate) nanoparticles occur?
Even if endocytosed nanoparticles cannot be detected, it does not exclude the
possibility that particles are being internalized. The nanoparticles have a high
nile red release relative to the total content in the particles, and the transfer of
nile red into cells is seemingly enhanced by a contact mediated mechanism [112,
113, 114, 143], suggesting an even higher release of nile red in the presence of
cells. Surface bound nanoparticles, or particles dispersed in the surrounding cell
medium, were rarely observed during CLSM imaging, in support of this theory. If
the majority of nile red is dissociated from the nanoparticles after 3 hours, there
is no way to determine where the particles are located and confirm the presence
of possible internalized particles with FCM and CLSM.
Because of the reasons outlined above, it has not been possible to assess if cellu-
lar uptake of nanoparticles occurred or not. This concluded my project work as
well [17], and the findings in this thesis show that the alterations in PEGylation
done in this study did not reduce nile red release enough for detection of particles
to be possible, probably caused by the low PEG surface density on all batches.
Alternative labeling with fluorescein dyes was tried out, but unfortunately none of
the labeling procedures were satisfactory. There were different problems with the
batches, but mainly the challenge was to attach proper amounts of fluorescein dye
to the particles. Recently, a protocol for synthesizing rhodamine tagged PBCA
nanoparticles, inspired by the work of Brambilla et al. [145] is showing promise in
our lab.
In light of what other authors have reported, there is reason to believe that
poly(alkyl cyanoacrylate) nanoparticles are internalized in cells [141, 145, 146, 147,
148], it has just not been possible to detect it with the nile red loaded nanopar-
ticles used in this study. Recent experiments with the rhodamine tagged PBCA
nanoparticles mentioned above are corroborative, they indicate internalization as
well. It is known that PEG density and conformation can influence cellular up-
take [141, 146, 147], and this will be interesting to investigate further with these
”new” nanoparticles.
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5.3 Nile red release from the nanoparticles
It was found that the nile red marker could dissociate from the nanoparticles and
into cell medium. Nile red leakage from different nanocarriers has also been re-
ported previously in the literature by several authors. [113, 114, 149, 150, 151] The
poly(alkyl cyanoacrylate) nanoparticles loose 45% or more of their encapsulated
nile red after 3 hours in cell medium. This corresponds well with how Xu et al.
found the relative nile red release from poly(D,L-lactide-co-glycolide) nanoparti-
cles after 3 hours in PBS with added FBS to be between 50 and 75% [114], and
also with the work of Delmas and colleagues, which showed approximately 40%
nile red release from lipid nanoparticles after 5 hours. [151] Furthermore, the re-
sults clearly demonstrate the ineptness of nile red as a nanoparticle marker for use
in flow cytometric and confocal microscopy analyses.
A denser PEG layer on the surface was hypothesized to reduce nile red release from
the particles. From my results, neither an increase in PEG chain length nor den-
sity, decreased the release to any extent. An explanation to why the hypothesis did
not hold can be that all particles in general had a low PEG surface density, with
the chains in a mushroom configuration, which did not provide a dense enough
hydrophilic layer to prevent nile red release, as illustrated in figure 5.2. High PEG
density and long chains has been found to slow down hydrophobic drug release
from poly(L-lactic acid) nanospheres [152], and PEG-poly(hexadecyl cyanoacry-
late) niosomes with higher PEG density released a hydrophobic drug slower than
those with lower density. [153] The drug release rate from poly(ethyl cyanoacrylate)
nanoparticles in human plasma decreased with increasing PEG chain length [154],
which also was true for the release rate from lipid nanocarriers. [155] Altogether,
this suggests that it is possible to decrease probe release from nanoparticles, both
by achieving a higher PEG density to force the chains into a brush conformation,
and by attaching longer PEGs to the surface.
Mechanism of hydrophobic probe release from the nanoparticles
Nile red can be seen as a model drug, in order to propose a mechanism for the
release of hydrophobic probes from poly(alkyl cyanoacrylate) nanoparticles. It is
demonstrated that nile red ends up intracellularly after nanoparticle incubation,
and it is thus a relevant system to look into for drug delivery purposes. In literature
it is claimed that drug release from biodegradable nanoparticles occur through
various processes: [107, 108, 109]
1. Desorption of drug bound to the surface
2. Diffusion through the nanoparticle matrix
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Figure 5.2: An illustration showing two nanoparticles with encapsulated nile red with
their PEG chains in a mushroom (left) and brush (right) conformation. At low grafting
density nile red is able to escape ”through” the PEG layer, whereas at high PEG surface
density nile red remains trapped in the core of the particle.
3. Nanoparticle matrix erosion
4. A combined erosion-diffusion process
The release profiles from poly(alkyl cyanoacrylate) nanoparticles found in the liter-
ature usually have two phases: An initial, rapid release and a second, slower, more
controlled release. [141, 154, 156, 157, 158, 159] There is evidence of an initial burst
release from the nanoparticles because of rapid nile red uptake in cells. [17, 143]
This is believed to be due to nile red located in a residual surface layer or close to
the surface of the particles. Initially, it was hypothesized that the particles were so
hydrophobic that nile red would prefer to remain in the particle core, rather than
diffusing out in the aqueous cell medium. Experimental evidence has shown that
this is not the case, since nile red could be released to the surrounding solution
in the presence of FBS, both demonstrated in this work and in studies of Xu et
al. [114] and Klymchenko et al. [149], suggesting the existence of serum proteins
with domains of equal or higher hydrophobicity as the nanoparticles. Moreover,
Klymchenko and colleagues showed that nile red release from nanoemulsions is a
very rapid process; dye leakage was detected already after 3 minutes [149], sup-
porting the theory of an initial burst release.
Further, there is evidence for a sustained release, since after 3 hours, approximately
50% of the nile red marker is still remaining in the particles. The cellular uptake
of nile red in cells after nanoparticle incubation has also been found to increase
with time. [143] This second phase of drug release is usually attributed to probe
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diffusion across the polymer matrix, polymer erosion or both. After dispersion
in cell medium, the particle size has been shown to increase [160], suggesting a
rapid protein adsorption on the surface and/or swelling caused by water seeping
into the particles. A consequence of swelling is that the environment surrounding
encapsulated nile red will be less hydrophobic, providing an explanation to why it
is also favorable for nile red further away from the surface to dissociate from the
particles. When the nile red surroundings become more hydrophilic, enhanced nile
red diffusion to the particle surface can occur. At the surface, nile red can associate
with hydrophobic parts of adsorbed proteins or other dispersed components, which
can further mediate nile red transfer into the solution. Polymer erosion can also
result in nile red being released from the nanoparticles, both because nile red
present in the surface eroding layers are liberated, and since partially hydrolyzed
polymers become more hydrophilic, and for the same reasons as outlined above,
this reduction in hydrophobicity of the nile red surroundings can contribute to
transfer nile red into the medium. The POCA particle did not transfer significantly
less nile red into cells, or reduced the release to cell medium compared to the PBCA
particles, altogether suggesting that the drug release during the first 3 hours is
governed by diffusion of nile red through the polymer matrix rather than polymer
erosion. Master student Andreas Bøe has established that neither the PBCA nor
POCA particles degraded to a large extent in cell medium after 4 hours [160],
supporting this theory.
Contribution from a contact-mediated mechanism?
As stated in the introduction of this thesis, there is evidence suggesting that
nanoparticle collisions with the cell membrane contribute to the transfer of nile
red into cells. A thorough study performed by master student Sofie Snipstad [143],
confirms that a contact based mechanism plays a dominant role in the delivery of
nile red to cells from PBCA nanoparticles. This can further increase our under-
standing of the release mechanism from the nanoparticles. It provides an additional
explanation for the rapid uptake in cells, and also why more nile red is delivered at
37◦C compared to 4◦C. Moreover, and maybe even more important in the context
of this thesis, is the fact that it can explain the difference between the particle
batches in their ability to deliver nile red to cells. The particle coated with the
longest PEG chain, and as previously outlined also with the thickest PEG layer,
transferred a significantly lower amount of nile red into cells than the rest of the
particles. This is not caused by reduced nile red release to cell medium, since
the relative release was comparable to the other batches. If collisions between
particles and the cell membrane enhance nile red transfer, the decreased nile red
delivery can be caused by a higher steric repulsion effect leading to fewer collisions.
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This is a promising discovery, since it indicates that the drug release profile of the
nanoparticles can be modified by alterations in PEGylation.
5.4 Cytotoxicity of poly(alkyl cyanoacrylate)
nanoparticles
In vitro experiments showed that toxicity in the PC3 cell line after exposure to
poly(alkyl cyanoacrylate) nanoparticles was largely dependent on the length of the
alkyl side chain in the polymer; the POCA particles were significantly less toxic
than their PBCA counterparts. All nanoparticles exhibited a dose response toxic-
ity, which is believed to be caused by release of degradation products, either intra-
or extracellularly. Literature tends to conclude that the toxicity mainly stems from
extracellular release of degradation products [66, 67], with particles adhering to
the cell membrane contributing more than those dispersed in solution. [67] There is
also reason to believe that remaining surfactant after synthesis induce toxicity, as
the measured cytotoxicity in general was higher than what is reported in literature
for similar nanoparticles. [67, 141, 142, 161, 165, 166]
Effect of monomer composition on cytotoxicity
Reduced toxicity of POCA nanoparticles compared to PBCA particles is corrob-
orated by how several studies have found poly(alkyl cyanoacrylate) nanoparticles
with shorter alkyl side chains to be more cytotoxic than those with longer side
chains. [66, 67, 161, 162] This effect of monomer composition is attributed to a
slower release of degradation products. The length of the alkyl side chain de-
termines the rate of poly(cyanoacrylate) degradation [61], and hence the libera-
tion of degradation products is expected to increase with decreasing side chain
length. Nanoparticles dispersed in cell medium will degrade to an alcohol and a
poly(cyanoacrylic acid), possibly accelerated by presence of esterases in FBS. [61,
62] These byproducts can cause cytotoxicity, both by formation of formaldehyde
and/or by diffusion of the alcohol into cells. Master student Andreas Bøe has
shown that POCA nanoparticles in cell medium degrade much slower than PBCA
particles. [160] Therefore, the concentration of degradation products surrounding
cells will be much lower after incubation with POCA particles, resulting in re-
duced toxicity compared to PBCA particles. An explanation to why byproducts
from the degradation of this bioresorbable polymer cause toxicity is provided by
Lherm et al. They found that degradation products had no effect on cell viability
in an equal concentration to where nanoparticles exhibited a distinct cytotoxic-
ity [67], and explained it by differences in cellular distribution of the degradation
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products: byproducts in solution become evenly distributed in the cell medium,
whereas nanoparticles can adhere to cell membranes and thereby cause high local
concentrations of degradation products.
Cytotoxicity can be caused by degradation of internalized nanoparticles, and not
only extracellular release of degradation products. Endocytosed particles will re-
side in the acidic environment of endosomes and/or lysosomes, which can affect the
polymer degradation rate. At pH 4, the degradation of the nanoparticles utilized
in this project was negligible during the same period of time used for the toxicity
studies. [160] Despite this pH being more acidic than what is found in both early
endosomes (pH∼6) and lysosomes (pH∼5) [163], it still establishes that lower pH
slows down polymer degradation. On the other hand, several enzymes are released
in the lysosomes, which possibly can catalyze the hydrolysis reaction of poly(alkyl
cyanoacrylates). More experiments are needed in order to determine how the
trade-off between these two effects influence the degradation rate of particles in
lysosomes, but it is plausible to believe that the relative difference in degrada-
tion rate between polymers with different alkyl side chain length still holds. This
means that cytotoxicity also can be caused by internalized nanoparticles, since the
POCA nanoparticles would degrade slower and release less degradation products
than the PBCA particles in endocytic vesicles as well.
Influence of surfactant on cytotoxicity
The surfactant used for emulsification of the particles during synthesis can influ-
ence cytotoxicity. [66, 126] Surfactants are capable of disrupting cell membranes
and thereby induce toxicity and lysis of cells. [164] There is a rather large discrep-
ancy between the concentrations where PBCA nanoparticles exhibited cytotoxicity
in this study, and what I have reviewed in the literature; an effect it is plausible
to attribute to residual surfactant from the synthesis. Kreuter et al. found the
LD50 value for PBCA nanoparticles in hepatocytes to be 400 µg/ml [161], and
a LD50 value of 100 µg/ml was obtained by Kusonwiriyawong et al. in dendritic
cells [165], a significantly higher tolerance than what was observed with the PBCA
particles used in this work. (LD50 values between 30 and 55 µg/ml) Zhang et al.
concluded that PEGylated PBCA particles were cytocompatible with human hep-
atoma cells at concentrations below 200 µg/ml after 4 hours exposure [142], and
concentrations up to 50 µg/ml PBCA particles have been shown not to reduce
cell viability in 3 other human hepatocellular cancer cell lines. [166] At a concen-
tration of 100 µg/ml no cell mortality was seen in both L929 fibroblasts after 3
hours exposure [67] and in a breast cancer cell line [141], contrasting the sharp
decrease in cell viability seen between 20 and 30 µg/ml in this study. Although
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different cell lines have been used in the above mentioned studies, and an effect of
cell type on cytotoxicity cannot be disregarded, it is more plausible to attribute
the large discrepancy between my results and what is reported in literature to
the surfactant, SDS. In previous studies of PBCA nanoparticles prepared by the
same synthesis procedure as in this work, cytotoxicity in PC3 cells was found to
be dependent on the type of surfactant; particles prepared with SDS were more
toxic than when TWEEN 80 was used as an emulsifier. [126] An influence of the
surfactant on the cytotoxicity is not contrasted by the reduced toxicity caused by
longer alkyl side chain in the polymer: The PBCA particles erode faster than the
POCA particles, and consequently they have a higher rate of surfactant release.
Influence of PEG chain length on cytotoxicity
The nanoparticle coated with the longest PEG chain (5000 Da) exhibited the
lowest toxicity amongst the PBCA particles, most probably caused by a stronger
steric repulsion effect between the particles and the cell membrane, resulting in
less particle adherence and thus lower local concentrations of degradation products
at the cell membrane. Other factors might also contribute to a slower release of
degradation products. Since the poly(alkyl cyanoacrylate) nanoparticles undergo
surface degradation, a thick PEG layer might shield the particle surface better
from the surrounding cell medium than a thinner PEG layer, reducing the rate of
polymer degradation. Nucleophilic groups that initiate hydrolysis of the polymer
or enzymes can have difficulties in coming close enough to the particle surface
because of steric hindrance provided by the long PEG chains. The mobility of the
degradation products can also be restricted by the long PEGs and thereby slowing
down the release.
Endocytosis of nanoparticles can provide an alternative explanation to why parti-
cles with the thickest PEG layer were less cytotoxic compared to particles coated
with shorter PEG chains. Increasing degree of PEGylation can decrease the cel-
lular uptake of nanoparticles [146, 141, 167] by reducing the interaction between
particles and cells due to the hydrophilic stealth coat. [168] If the cytotoxicity is
caused by endocytosed nanoparticles, a smaller number of internalized particles
would reduce toxicity.
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Relevance of in vitro cytotoxicity studies
To summarize, it can be stated that somewhat higher cytotoxicity than expected
was observed after exposure to the nanoparticles, probably due to an influence of
residual surfactant from the synthesis. In evaluating the significance of these re-
sults for using the particles as carriers of contrast or therapeutic agent, it has to be
stressed that in vitro studies cannot be directly related to in vivo toxicity. The ra-
tio of nanoparticles to cells during in vitro experiments is significantly higher than
after in vivo administration. Moreover, if nanoparticle degradation products are
responsible for the cytotoxicity of poly(alkyl cyanoacrylate) nanoparticles, under
dynamic in vivo conditions these products can be eliminated from the nanoparticle
location to a greater extent than in static in vitro experiments, thereby reducing
the time of exposure of degradation products to cells and possibly minimizing
adverse effects.
5.5 General considerations for further work
In light of all presented results in this thesis, lastly, I will try to make some
general considerations on what can be learned from this work in order to optimize
the poly(alkyl cyanoacrylate) nanoparticles for use as a drug delivery system and
which properties it is important to improve.
For the function of the proposed nanocarrier, my results suggest that the particles
have a too low PEG density both to obtain sufficient circulation times and to min-
imize drug leakage during circulation. It should therefore be prioritized to improve
the PEG density on the particles, as this feature is essential for the particles’ func-
tionality in vivo. Higher PEG densities have been reported on PBCA particles
prepared by the miniemulsion process [132], implicating that it is indeed possi-
ble to achieve, either by changing the protocol for synthesis or the utilized PEG
type. There are also positive implications for the function of the nanoparticles
from this study. An important barrier for efficient drug delivery from endocytosed
nanomedicines is that the drug must be able to escape from endocytic vesicles.
The proposed mechanism of drug transfer from the nanoparticles and into cells
does not rely on endocytosis, and may therefore provide a promising method for
intracellular drug delivery. For this to be a good strategy, a high release of drug
during systemic circulation should be prevented. It is hypothesized that a denser
PEG coating with chains in a brush conformation, can increase the nanoparticles’
stability. The clinical relevance of the system has been demonstrated by showing
that more nile red is delivered to cells when it is encapsulated in the nanoparticles
compared to when administered alone. [143]
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Safety of the proposed delivery system should be a main concern. Poly(alkyl
cyanoacrylate) nanoparticles should degrade slowly enough to prevent high local
concentrations of degradation products occurring and release degradation products
at a rate which they can be metabolized without causing acute toxic effects. [67]
From the in vitro toxicity studies, the POCA particles seem like the best candidate
in this aspect. On the other hand, almost no degradation of POCA particles was
detected in blood serum, even after three weeks [160], which on further reflection
suggests that this polymer has a too slow degradation rate to be clinically relevant.
(You do not want nanocarriers left in the blood stream more than three weeks after
administration.) Instead of choosing POCA as the composition of the nanocarrier,
my recommendation is rather to work on finding an alternative surfactant to SDS,
to see if this will reduce the toxic effects caused by the PBCA nanoparticles. As
higher tolerance of PBCA particles are frequently reported in the literature [67,
141, 142, 161, 165, 166], there is reason to believe that this strategy can work.
For multiple dosing, the use of a faster degrading polymer is also more suitable
to avoid polymer overloading of the cells. In vivo studies are needed in order to
get a more relevant picture of the toxicity. If the PBCA particles exhibit too high
toxicity in animals, and no alternative surfactant can be found, it is possible to
try an intermediate chain length, like isohexyl. Poly(isohexyl nanoparticles) have
made it to phase III clinical trials (Clinical trial ID: NCT01655693), implying that
the polymer is biocompatible.
Another lesson learned from this study is that the PEG chain length, and thereby
the relative PEG layer thickness, is an important factor to consider. The results
suggest that coating of the particle with a longer PEG chain can provide similar,
or even better protected surfaces, than with a shorter PEG chain present in a
higher density. This is of significance, because the fewer PEG chains that can be
used to achieve the same effect the better, as the amount of non-biodegradable
PEGs is minimized. It has been demonstrated in this work that an increase in
PEG layer thickness reduce toxicity and modify the delivery of nile red to cells,
further confirming the significance of the PEG layer for nanoparticle function.
6 Conclusion
This study has investigated the effect of particle PEGylation and monomer com-
position on cellular uptake, nile red release and cytotoxicity. The estimated values
for PEG chain density revealed low PEG surface coverage on all utilized parti-
cles, hence making it difficult to make any general conclusions about the effect of
the PEG layer, since all PEG chains were present in the mushroom conformation,
independent on number of PEGs attached and the molecular weight of the PEG
used. Nevertheless, it was established that the alterations in PEGylation done
in this study were not sufficient to reduce the nile red release from the particles
enough for detection of endocytosis to be possible, probably caused by the low
PEG surface density on all particles. It was also demonstrated that 45% or more
of the encapsulated nile red marker is released to cell medium after 3 hours. This
result suggests that a higher PEG surface coverage is needed in order to minimize
release of hydrophobic drugs from the particles during circulation. Further studies
are needed to determine if it is also necessary to increase the PEG density for
preventing activation of complement and uptake by the MPS. As the PEG density
for chains of equal length was shown not to depend on the amount added during
synthesis, the results clearly imply that a different strategy than addition of more
PEG is needed to achieve a denser PEG layer. It is also recommended that longer
PEG chains are used, since these chains give a relatively thicker PEG layer. This
is especially important if it turns out difficult to achieve higher PEG densities,
as my results indicate that longer PEG chains can provide similar shielding of a
surface as a shorter chain, even when present in lower densities.
Through experiments conducted it is clear that monomer composition had a sig-
nificant influence on the cytotoxicity after nanoparticle exposure. The POCA
particles with the longest alkyl side chain were considerably less cytotoxic than
the PBCA particles, implicating that the release of degradation products is re-
sponsible for the induced toxicity. A contribution from residual surfactant should
also be taken into consideration, as the observed cytotoxicity in general was higher
than what is reported for similar nanoparticles in the literature. It should therefore
be worked with finding an alternative surfactant to SDS, which functions equally
well in synthesis, but induce less toxicity in cells.
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A PEG chemical structures
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B Supporting figures for experiments with fluo-
resceinamine particle batch 66
Figure B.1: Overlay histogram obtained in FCM analyses of PC3 cells incubated with
fluoresceinamine labeled nanoparticle batch 66 for 3 hours at 37◦C and 4◦C. The fluo-
rescence intensity is shown both after 3 times rinsing with PBS, and after additional 3
times centrifugation.
Figure B.2: CLSM image of PC3 cells after addition of the modified nanoparticle batch
66. Fluoresceinamine fluorescence is depicted in green, and the scale bar is 20 µm.
Appendix C 105
C Nile red fluorescence from different spectral
intervals in FCM
(a) Nile red fluorescence intensity detected in
a 582 nm filter with 15 nm band pass.
(b) Nile red fluorescence intensity detected in
a 620 nm filter with 30 nm band pass.
Figure C.1: Overlay histograms obtained in FCM analyses of PC3 cells incubated with
nile red labeled nanoparticle batch 73 for 3 hours at 37◦C and 4◦C respectively. The
fluorescence intensity is detected in two channels, both after 3 times rinsing with PBS,
and after additional 3 times centrifugation. Both channels show similar fluorescence
patterns, but higher intensity is detected in the 620 nm filter. What is shown here was
representative for all the nile red labeled nanoparticles.
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D Standard curves from spectrophotometric
measurements
(a) Standard curve for nile red dissolved in hexadecane
(b) Standard curve for nile red dissolved in THF
Figure D.1: Standard curves of nile red concentration versus fluorescence intensity, ob-
tained in spectrophotometric measurements of nile red dissolved in hexadecane (a) and
THF (b).
